var title_f36_33_37392="Laparoscopic cystectomy cd";
var content_f36_33_37392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic ovarian cystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (C) Alternatively, the cyst wall can be grasped and rotated to separate it from the ovarian cortex. (D) The cyst is removed and the ovary is left to heal by secondary intention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37392=[""].join("\n");
var outline_f36_33_37392=null;
var title_f36_33_37393="Patient information: Hiatal hernia (The Basics)";
var content_f36_33_37393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15877\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/50/4900\">",
"         Hiatal hernia",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/7/30843\">",
"           Medicines used to treat acid reflux",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hiatal hernia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hiatal-hernia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12373454\">",
"      <span class=\"h1\">",
"       What is a hiatal hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hiatal hernia is what doctors call it when a part of the stomach moves up into the chest area. Normally, the stomach sits below the diaphragm, the layer of muscle that separates the organs in the chest from the organs in the belly. The esophagus, the tube that carries food from the mouth to the stomach, passes through a hole in the diaphragm. In people with a hiatal hernia, the stomach pushes up through that hole, too.",
"     </p>",
"     <p>",
"      There are 2 types of hiatal hernia (",
"      <a class=\"graphic graphic_figure graphicRef78791 \" href=\"mobipreview.htm?4/50/4900\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Sliding hernia &ndash; A sliding hernia happens when the top of the stomach squeezes up into the space above the diaphragm. This is the most common type of hiatal hernia.",
"       </li>",
"       <li>",
"        Paraesophageal hernia &ndash; A paraesophageal hernia happens when the top of the stomach folds up against the esophagus, creating a pouch. This is not very common, but it can be serious. If left untreated, this type of hernia can damage the top of the stomach.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12373461\">",
"      <span class=\"h1\">",
"       What are the symptoms of a hiatal hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hiatal hernias do not usually cause symptoms. In some cases, though, hiatal hernias cause stomach acid to leak into the esophagus. This is called acid reflux or gastroesophageal reflux, and it can cause symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Burning in the chest, known as heartburn",
"       </li>",
"       <li>",
"        Burning in the throat or an acid taste in the throat",
"       </li>",
"       <li>",
"        Stomach or chest pain",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        A raspy voice or a sore throat",
"       </li>",
"       <li>",
"        Unexplained cough",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12373468\">",
"      <span class=\"h1\">",
"       Is there a test for hiatal hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, but doctors do not usually test for hiatal hernia. Instead, most people learn they have a hiatal hernia when they are having tests to find the cause of symptoms, or for other reasons. For instance, some people find out they have a hiatal hernia when they have an X-ray. Others find out when their doctor puts a tube with a tiny camera down their throat (called an endoscopy) (",
"      <a class=\"graphic graphic_figure graphicRef75392 \" href=\"mobipreview.htm?36/39/37490\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12373475\">",
"      <span class=\"h1\">",
"       How are hiatal hernias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The hiatal hernia itself is not usually treated. But people who have symptoms caused by a hiatal hernia can get treated for their symptoms.",
"     </p>",
"     <p>",
"      Treatment for symptoms involves taking the medicines that are used for acid reflux (",
"      <a class=\"graphic graphic_table graphicRef78918 \" href=\"mobipreview.htm?30/7/30843\">",
"       table 1",
"      </a>",
"      ). If those treatments do not work, doctors sometimes will do surgery to pull the stomach back down and repair the hole in the diaphragm so the stomach does not slide up again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12373542\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/33/37393?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15877 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37393=[""].join("\n");
var outline_f36_33_37393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12373454\">",
"      What is a hiatal hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12373461\">",
"      What are the symptoms of a hiatal hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12373468\">",
"      Is there a test for hiatal hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12373475\">",
"      How are hiatal hernias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12373542\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/50/4900\">",
"      Hiatal hernia",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/7/30843\">",
"        Medicines used to treat acid reflux",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37394="Rigid bronchoscopy: Instrumentation";
var content_f36_33_37394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rigid bronchoscopy: Instrumentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37394/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/33/37394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid bronchoscopy is a technique that visualizes the trachea and proximal bronchi. It is usually performed in the operating room under general anesthesia. Rigid bronchoscopy is most commonly used to manage patients who have obstruction of either their trachea or a proximal bronchus, since the rigid bronchoscope&rsquo;s large lumen facilitates suctioning and the removal of debris, or for interventional procedures such as insertion of airway stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37394/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rigid bronchoscopes, equipment for visualization, and accessory instruments are reviewed here. Techniques of rigid bronchoscopic intubation are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7412?source=see_link\">",
"     \"Rigid bronchoscopy: Intubation techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RIGID BRONCHOSCOPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rigid bronchoscope is also known as an open tube bronchoscope, open tube, straight bronchoscope, or ventilating bronchoscope. It is a rigid, straight, hollow metal tube that is available in several sizes. Its purpose is to provide access to the airways.",
"   </p>",
"   <p>",
"    The external diameter of a rigid bronchoscope varies from 2 to 14 mm, wall thickness ranges from 2 to 3 mm, and length varies from a very short tube (for pediatric cases) to a long or extra long tube (for adults). Tubes with an extra large diameter have been developed for exceptional cases of tracheobronchomalacia, but they are not readily available.",
"   </p>",
"   <p>",
"    Most rigid bronchoscopes are the same diameter from the proximal to the distal end, although some have a beveled or tapered tip to lift the epiglottis during intubation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7412?source=see_link\">",
"     \"Rigid bronchoscopy: Intubation techniques\"",
"    </a>",
"    .) Variations in the tip design also facilitate the dilation of airway strictures. Most rigid bronchoscopes are round when visualized in cross-section, with external side ports that permit the introduction of suction catheters, laser fibers, and ventilation (",
"    <a class=\"graphic graphic_picture graphicRef53603 \" href=\"mobipreview.htm?28/58/29603\">",
"     picture 1",
"    </a>",
"    ). A few are almost oval. A small internal channel exists in some rigid bronchoscopes, through which the rigid telescope passes. Others are simply an empty tube. Some rigid bronchoscopes can analyze exhaled gases.",
"   </p>",
"   <p>",
"    Many bronchoscopists use only a single manufacturer's rigid bronchoscope, which may come in one or two varying sizes. Other bronchoscopists prefer to have a set of rigid bronchoscopes with different lengths and diameters (",
"    <a class=\"graphic graphic_picture graphicRef61399 \" href=\"mobipreview.htm?37/39/38526\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67737 \" href=\"mobipreview.htm?24/31/25085\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79780 \" href=\"mobipreview.htm?38/45/39644\">",
"     picture 3",
"    </a>",
"    ). Such bronchoscopists generally have long rigid bronchoscopes with distal side ports that facilitate ventilation of the contralateral lung when working within a main bronchus (ie, ventilating rigid bronchoscopes), as well as short rigid bronchoscopes without ventilating side ports that are used solely when working in the trachea (ie, non-ventilating rigid bronchoscopes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37394/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VISUALIZING EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During rigid bronchoscopy, a rigid telescope and light source are generally inserted through a rigid bronchoscope to visualize the airways. However, a few systems allow direct visualization through the rigid bronchoscope using light conducted through a tube that extends the length of the rigid bronchoscope or through a prism at the proximal end. A flexible bronchoscope inserted through the rigid bronchoscope is a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rigid telescopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid telescopes visualize the airways at angles of 0, 30, 40, 50, 90, 135, and 180 degrees with respect to the axis of the telescope. This facilitates visualization of the upper lobe, lower lobe, and mainstem bronchi bilaterally (",
"    <a class=\"graphic graphic_figure graphicRef70935 \" href=\"mobipreview.htm?19/6/19552\">",
"     figure 2",
"    </a>",
"    ). The Hopkins lens rigid telescope is the most popular type of rigid telescope. The Hopkins rod telescope is an alternative type of rigid telescope that provides superb visualization of the airway and is available in multiple lengths and diameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37394/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Light source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illumination is extremely important during rigid bronchoscopy, since visualization tends to be poor due to the pinkish-red color of the airway mucosa, the presence of blood,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of distal airway abnormalities. A cold light source (ie, xenon and halogen lamps) is the most frequently used illumination device in rigid bronchoscopy. Newer light sources have devices that regulate the amount of applied light (ie, automatic light intensity regulators, automatic irises), thereby minimizing glare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Video equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video supplements rigid bronchoscopy. It is ideal for teaching and documenting procedures, as well as allowing viewing by multiple individuals. Video imaging is enhanced by the high quality of the optics in a rigid telescope. Single chip or three-chip video cameras can be easily connected to the proximal aspect or eyepiece of a rigid telescope via direct connection devices, Snap-on lenses, or standard C- mounts. Alternatively, a flexible bronchoscope with digital video capability can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACCESSORY INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory instruments that may be used during rigid bronchoscopy include forceps for biopsy, forceps that facilitate foreign-body removal, suction tubing, and instruments used to insert and remove airway prostheses (eg, stents).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21111178\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rigid bronchoscopy is a technique that visualizes the trachea and proximal bronchi. It is most commonly used to manage patients who have obstruction of either their trachea or a proximal bronchus, since the rigid bronchoscope&rsquo;s large lumen facilitates suctioning and the removal of debris, or for interventional procedures such as insertion of airway stents. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During rigid bronchoscopy, a rigid telescope and light source are generally inserted through a rigid bronchoscope to visualize the airways. However, a few systems allow direct visualization through the rigid bronchoscope using light conducted through a tube that extends the length of the rigid bronchoscope or through a prism at the proximal end. A flexible bronchoscope inserted through the rigid bronchoscope is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rigid bronchoscopes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Visualizing equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accessory instruments may be necessary during rigid bronchoscopy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Accessory instruments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37394/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37394/abstract/2\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37394/abstract/3\">",
"      Dumon JF, Shapshay S, Bourcereau J, et al. Principles for safety in application of neodymium-YAG laser in bronchology. Chest 1984; 86:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37394/abstract/4\">",
"      Berci G. Chevalier Jackson Lecture. Analysis of new optical systems in bronchoesophagology. Ann Otol Rhinol Laryngol 1978; 87:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4390 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37394=[""].join("\n");
var outline_f36_33_37394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21111178\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RIGID BRONCHOSCOPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VISUALIZING EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rigid telescopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Light source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Video equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACCESSORY INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21111178\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4390|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25085\" title=\"figure 1\">",
"      Efer Dumon rigid bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/6/19552\" title=\"figure 2\">",
"      Lateral viewing telescope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4390|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/58/29603\" title=\"picture 1\">",
"      Rigid bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/39/38526\" title=\"picture 2\">",
"      Karl Storz rigid bronchoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/45/39644\" title=\"picture 3\">",
"      Efer Dumon rigid tube",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7412?source=related_link\">",
"      Rigid bronchoscopy: Intubation techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37395="Endometrial tissue on the thoracic surface of the diaphragm";
var content_f36_33_37395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Endometrial tissue on the thoracic surface of the diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thoracoscopic image of endometrial tissue on the thoracic surface of the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Ciriaco P, Negri G, Libretti L, et al. Surgical treatment of catamenial pneumothorax: a single centre experience, Interact Cardiovasc Thorac Surg 2009; 8:349, by permission of the European Association for Cardio-Thoracic Surgery. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37395=[""].join("\n");
var outline_f36_33_37395=null;
var title_f36_33_37396="Cysts in LAM";
var content_f36_33_37396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph showing multiple cysts (arrow) in the lung of a patient with lymphangioleiomyomatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37396=[""].join("\n");
var outline_f36_33_37396=null;
var title_f36_33_37397="Diphenoxylate and atropine: Pediatric drug information";
var content_f36_33_37397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenoxylate and atropine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"    see \"Diphenoxylate and atropine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/39/11892?source=see_link\">",
"    see \"Diphenoxylate and atropine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"      see \"Diphenoxylate and atropine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (as diphenoxylate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-12 years:",
"     <b>",
"      Liquid:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Only the liquid product is recommended for children under 13 years of age; do not exceed recommended doses; reduce dose as soon as symptoms are initially controlled; maintenance doses may be as low as 25% of initial dose; if no improvement within 48 hours of therapy, diphenoxylate is not likely to be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 0.3-0.4 mg/kg/day in 4 divided doses (maximum: 10 mg/day)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;2 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     2 years (11-14 kg): 1.5-3 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3 years (12-16 kg): 2-3 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4 years (14-20 kg): 2-4 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     5 years (16-23 kg): 2.5-4.5 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-8 years (17-32 kg): 2.5-5 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9-12 years (23-55 kg): 3.5-5 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternative pediatric dosing: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;2 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     2-5 years: 2 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     5-8 years: 2 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     8-12 years: 2 mg 5 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 5 mg (2 tablets or 10 mL) 4 times/day until control achieved (maximum: 20 mg/day); then reduced dose as needed; maintenance: 5-15 mg/day in 2-3 divided doses; some patients may be controlled on doses as low as 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed recommended doses; reduce dose once symptoms are initially controlled; acute diarrhea usually improves within 48 hours; if chronic diarrhea dose not improve within 10 days at maximum daily doses of 20 mg, diphenoxylate is not likely to be effective.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg per 5 mL (5 mL, 10 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lomotil&reg;: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg per 5 mL (60 mL) [contains alcohol 15%; cherry flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lomotil&reg;: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F161178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered with food to decrease GI upset; use plastic dropper provided when measuring liquid;",
"     <b>",
"      Note:",
"     </b>",
"     Dropper has a 2 mL (1 mg) capacity and is calibrated in increments of",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     mL (0.25 mg)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; dispense liquid only in original container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil&reg; may be confused with LaMICtal&reg;, LamISIL&reg;, lamoTRIgine, Lanoxin&reg;, Lasix&reg;, loperamide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomotil [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomotil: Brand name for diphenoxylate [U.S., Canada, and multiple international markets], but also the brand name for loperamide [Mexico, Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, drowsiness, euphoria, flushing, headache, hyperthermia, lethargy, malaise, restlessness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, dry skin, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, anorexia, gum swelling, nausea, pancreatitis, paralytic ileus, toxic megacolon, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenoxylate, atropine, or any component; severe liver disease, obstructive jaundice, dehydration, narrow-angle glaucoma, diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. Do not use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with dehydration, cirrhosis, hepatorenal disease, renal dysfunction, and acute ulcerative colitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in conjunction with fluid and electrolyte therapy in children and in adults when appropriate. In case of severe dehydration or electrolyte imbalance, withhold diphenoxylate/atropine treatment until corrective therapy has been initiated. Inhibiting peristalsis may lead to fluid retention in the intestine aggravating dehydration and electrolyte imbalance. Reduction of intestinal motility may be deleterious in diarrhea resulting from",
"     <i>",
"      Shigella",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     , toxigenic strains of",
"     <i>",
"      E. coli",
"     </i>",
"     and from pseudomembranous enterocolitis associated with broad spectrum antibiotics; use is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in children. Younger children (especially those with Down syndrome) may develop signs of atropinism (dry skin and mucous membranes, thirst, hyperthermia, tachycardia, urinary retention, flushing) even at the recommended dosages. Overdose in children may result in severe respiratory depression (young children may be at greater risk ), coma, and possibly permanent brain damage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If acute diarrhea does not clinically improve within 48 hours, this medication is unlikely to be effective and should be discontinued; if chronic diarrhea is not improved symptomatically within 10 days at maximum dosage, control is unlikely with further use. Prolonged use may result in tolerance to antidiarrheal effects and physical or psychological dependence; abrupt discontinuation may cause withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2999114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not noted in animal studies; decreased maternal weight, fertility and litter sizes were observed. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel frequency, signs and symptoms of atropinism, fluid and electrolytes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphenoxylate inhibits excessive GI motility and GI propulsion; commercial preparations contain a subtherapeutic amount of atropine to discourage abuse",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Antidiarrheal effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 45-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tolerance to antidiarrheal effects may occur with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atropine: See Atropine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diphenoxylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: Major metabolite (diphenoxylic acid) may be excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via ester hydrolysis to diphenoxylic acid (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diphenoxylate: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diphenoxylic acid: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak serum concentration: &sim;2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: Primarily (49%) in feces (via bile); &sim;14% is excreted in urine; &lt;1% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/39/11892?source=see_link\">",
"      see \"Diphenoxylate and atropine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take as directed; do not exceed recommended dosage. If diarrhea does not improve within 48 hours, notify prescriber. Avoid alcohol and the herbal medicine St John's wort; may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may be habit-forming; avoid abrupt discontinuation after prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naloxone reverses toxicity due to diphenoxylate; Lomotil&reg; solution also contains sorbitol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13237 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37397=[""].join("\n");
var outline_f36_33_37397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052324\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052317\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161124\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161178\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052328\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052320\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052327\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161185\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161182\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052316\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052315\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299213\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161133\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161135\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2999114\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052323\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052314\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052330\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052331\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052322\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052333\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=related_link\">",
"      Diphenoxylate and atropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/39/11892?source=related_link\">",
"      Diphenoxylate and atropine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37398="Histology fibrotic foci";
var content_f36_33_37398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Photomicrographs of histologic features of usual interstitial pneumonia of IPF lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fibrotic foci (arrows) are hallmarks of usual interstitial pneumonia (Left: H and E stain; Right: Masson's trichrome stain-collagen is stained blue).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ganesh Raghu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37398=[""].join("\n");
var outline_f36_33_37398=null;
var title_f36_33_37399="Piroxicam: Pediatric drug information";
var content_f36_33_37399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piroxicam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"    see \"Piroxicam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/0/18437?source=see_link\">",
"    see \"Piroxicam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feldene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Piroxicam&reg;;",
"     </li>",
"     <li>",
"      Dom-Piroxicam;",
"     </li>",
"     <li>",
"      Novo-Pirocam;",
"     </li>",
"     <li>",
"      Nu-Pirox;",
"     </li>",
"     <li>",
"      PMS-Piroxicam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"      see \"Piroxicam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 0.2-0.3 mg/kg/day once daily; maximum dose: 15 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 10-20 mg/day once daily; although associated with increase in GI adverse effects, doses &gt;20 mg/day have been used (ie, 30-40 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feldene&reg;: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088596.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088596.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food or milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory diseases and rheumatoid disorders; dysmenorrhea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Feldene&reg; may be confused with FLUoxetine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Piroxicam may be confused with PARoxetine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flogene [Brazil] may be confused with Flogen brand name for naproxen [Mexico]; Florone brand name for diflorasone [Germany, Greece]; Flovent brand name for fluticasone [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F210709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Reported with piroxicam or other NSAIDS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, bleeding, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, perforation, ulcer, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylactic reaction, angina exacerbated, angioedema, aplastic anemia, arrhythmia, aseptic meningitis, blurred vision, bone marrow suppression, CHF, cystitis, decreased hearing, dyspnea, epistaxis, erythema multiforme, gastritis, hallucinations, hemolytic anemia, hepatitis, hyperkalemia, hypertension, interstitial nephritis, jaundice, leukopenia, liver failure, MI, nephrotic syndrome, pancreatitis, pancytopenia, peripheral neuropathy, photosensitivity, polydipsia, polyuria, renal failure, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to piroxicam or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased hepatic function; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia (due to occult or gross blood loss from the GI tract, fluid retention, or other effect on erythropoiesis) may occur; monitor hemoglobin and hematocrit in patients receiving long-term therapy. Use with caution and monitor carefully in patients with coagulation disorders or those receiving anticoagulants, as NSAIDs inhibit platelet aggregation and may prolong bleeding time.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral use: NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use; smoking; use of alcohol; and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A serum sickness-like reaction can rarely occur; watch for arthralgias, pruritus, fever, fatigue, and rash. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F210697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9513525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies piroxicam as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, BUN, serum creatinine, liver enzymes; periodic ophthalmologic exams with chronic use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 3-5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk at a concentration of about 1% to 3% of maternal plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted as metabolites and unchanged drug (&sim;5% to 10%) in the urine; small amount excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/0/18437?source=see_link\">",
"      see \"Piroxicam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of piroxicam.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Piroxicam may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; or weight gain.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12711 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37399=[""].join("\n");
var outline_f36_33_37399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709215\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210654\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054978\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054972\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210633\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210618\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874786\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054982\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054981\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198225\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210709\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054971\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054970\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210627\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054987\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210629\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9513525\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054977\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054969\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054984\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054985\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054976\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12711|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=related_link\">",
"      Piroxicam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/0/18437?source=related_link\">",
"      Piroxicam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37400="Molec progress oral CA";
var content_f36_33_37400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Chemical, pathologic, and molecular progression of oral cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) shows clinical progression of oral cancer. Panel B) depicts the histologic progression from normal-appearing mucosa to invasive cancer. Normal-appearing mucosa already harbors early genetic changes (Panel C), often with loss of 9p21 and inactivation of p16. Further clinical progression through dysplasia is associated with further genetic changes. Carcinoma in situ often harbors most of the genetic changes described in invasive carcinoma.",
"    <div class=\"footnotes\">",
"     LOH: loss of heterozygosity.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Joseph A Califano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37400=[""].join("\n");
var outline_f36_33_37400=null;
var title_f36_33_37401="Overview of diaper dermatitis in infants and children";
var content_f36_33_37401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of diaper dermatitis in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Kimberly A Horii, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Trisha A Prossick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37401/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/33/37401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaper dermatitis is a general term used to describe any inflammatory skin eruption that develops in the diaper-covered region. It is synonymous with diaper rash, napkin dermatitis, and nappy rash. Although there are several causes of diaper dermatitis (",
"    <a class=\"graphic graphic_table graphicRef81540 \" href=\"mobipreview.htm?35/17/36123\">",
"     table 1",
"    </a>",
"    ), \"generic\" diaper dermatitis is most often considered an irritant contact dermatitis (eg, a rash that results from localized physical, chemical, or mechanical irritation). Diaper dermatitis usually affects infants and toddlers, although it can affect any individual who wears a diaper.",
"   </p>",
"   <p>",
"    An overview of the epidemiology, causes, treatment, and prevention of diaper dermatitis will be reviewed here. Contact dermatitis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaper dermatitis is one of the most common skin disorders of infants and children. The reported incidence and age of onset vary worldwide, related to differences in diaper use, toilet training, hygiene, and child-rearing practices in different countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, diaper dermatitis represents 10 to 20 percent of all skin disorders evaluated by the general pediatrician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. According to the 1990-1997 National Ambulatory Medical Care Survey, there were 8.2 million pediatric visits for diaper dermatitis, and the calculated risk of developing diaper dermatitis throughout childhood was one in four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/3\">",
"     3",
"    </a>",
"    ]. In infants, the estimated prevalence of diaper dermatitis ranges from 7 to 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/3\">",
"     3",
"    </a>",
"    ]. Diaper dermatitis can develop as early as one week of age, but the peak incidence occurs between 9 and 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaper dermatitis is a general term that encompasses numerous skin conditions occurring in the diaper area (",
"    <a class=\"graphic graphic_table graphicRef81540 \" href=\"mobipreview.htm?35/17/36123\">",
"     table 1",
"    </a>",
"    ). There are two major categories of diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rashes associated with or worsened by the diaper",
"     </li>",
"     <li>",
"      Rashes that occur regardless of diaper use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diaper associated",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Irritant dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant dermatitis is the most common form of dermatitis associated with diaper use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7\">",
"     7",
"    </a>",
"    ]. Clinical manifestations range from asymptomatic erythema to painful scaling papules and superficial erosions.",
"   </p>",
"   <p>",
"    Irritant diaper dermatitis typically occurs on convex skin surfaces that are in direct contact with the diaper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These locations include the buttocks, lower abdomen, genitalia, and upper thighs (",
"    <a class=\"graphic graphic_figure graphicRef58898 \" href=\"mobipreview.htm?29/26/30126\">",
"     figure 1",
"    </a>",
"    ). The skin folds (areas not in direct contact with the diaper) are classically spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1\">",
"     1",
"    </a>",
"    ]. \"Tidewater dermatitis\" describes erythema and scaling at the diaper margin due to friction and cycles of wetness and dryness in the affected areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jacquet's erosive dermatitis and granuloma gluteale infantum are rare dermatoses that occur in the diaper area and likely represent the severe end of the spectrum of irritant diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jacquet's erosive diaper dermatitis is characterized by well-demarcated papules, nodules, and punched-out ulcerations in the perineal region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/12\">",
"       12",
"      </a>",
"      ]. Several factors contributing to the development of Jacquet's erosive dermatitis have been proposed, including urinary incontinence, infrequent diaper changing, and chronic stooling. Jacquet's diaper dermatitis usually is treated in the same manner as irritant diaper dermatitis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Granuloma gluteale infantum presents with characteristic reddish-purple nodules in the inguinal folds, scrotum, buttocks, and medial thighs and is usually seen between two and nine months of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Numerous precipitating factors have been identified, including the use of high-potency topical corticosteroids and preexisting candidal infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Although granuloma gluteale infantum may clinically resemble a neoplastic process, it is considered a benign inflammatory dermatosis. Skin biopsy may help confirm the diagnosis. It may improve with the avoidance of inciting factors and aggressive barrier protection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Candidal dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If irritant dermatitis is left untreated for more than three days, it may become secondarily infected with microorganisms such as Candida albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Candidal infections classically present with beefy red plaques, satellite papules, and superficial pustules that leave a collarette of scale once ruptured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to irritant diaper dermatitis, candidal infections commonly involve the skin folds (",
"    <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"mobipreview.htm?35/41/36501\">",
"     picture 1A-B",
"    </a>",
"    ). There also may be a history of diarrhea, recent antibiotic use, or oral thrush. Diagnosis usually is based on the clinical presentation, but may be confirmed by potassium hydroxide preparation demonstrating pseudohyphae or by fungal culture (",
"    <a class=\"graphic graphic_picture graphicRef79879 graphicRef50344 \" href=\"mobipreview.htm?20/29/20950\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Persistent candidal diaper rash in young children may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immune deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22553?source=see_link&amp;anchor=H571998#H571998\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Clinical features of AIRE deficiency/APECED'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Allergic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis to allergens in the diaper, including dye, has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/18-21\">",
"     18-21",
"    </a>",
"    ], but the prevalence is unknown. Clinical features include well-demarcated erythema, papules with scale, vesicles, or erosions in the diaper region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Lucky Luke\" or \"cowboy holster\" dermatitis is a form of allergic contact dermatitis in the diaper region characterized by its pattern of involvement, which resembles a cowboy's gun belt with triangular erythema located beneath the side bands (used to secure the diaper) on the lateral buttocks, upper lateral thighs, and flanks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ]. Allergic contact dermatitis due to diaper dye usually occurs in a distribution that corresponds to the distribution of dye in the diaper (eg, hips, buttocks, inguinal area,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suprapubic area).",
"   </p>",
"   <p>",
"    If allergic contact dermatitis is suspected, skin patch testing may aid in identifying the underlying etiologic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Allergic contact dermatitis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nondiaper associated",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Seborrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is common during infancy. Clinical features include well-circumscribed erythematous papules and plaques with greasy yellow scale most prominent in the skin folds (",
"    <a class=\"graphic graphic_figure graphicRef62588 \" href=\"mobipreview.htm?40/35/41534\">",
"     figure 2",
"    </a>",
"    ). In the diaper region, the inguinal creases are mainly involved. Seborrheic dermatitis is rarely isolated to the diaper area. Most infants also have involvement of the scalp (\"cradle cap\"), face, neck, and other skin folds (axillae, antecubital fossa, and popliteal fossa). Seborrheic dermatitis usually responds to short-term topical therapy with low-potency corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of dermatitis\", section on 'Seborrheic dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis usually spares the diaper area since the diaper provides a moist environment that hydrates the underlying skin, preventing the development of eczematous dermatitis. When the diaper area is affected by atopic dermatitis, signs of chronic scratching (eg, increase in skin lines and excoriations) may be observed. Atopic dermatitis usually is present elsewhere on the body, and there is typically a history of pruritus and a family history of atopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bacterial infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impetigo &mdash; Impetigo (secondary bacterial infection) also may develop in the diaper region. Hallmarks of impetigo include 1 to 2 mm fragile pustules and honey-colored, crusted erosions. Bullous impetigo describes large, flaccid, pus-filled bullae that tend to rupture easily, leaving erosions with a collarette of scale. Impetigo usually is caused by Staphylococcus aureus with or without group A streptococcal (GAS) coinfection. Gram stain and bacterial culture of a pustule should be performed to confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=see_link\">",
"       \"Impetigo\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Young infants with bacterial diaper dermatitis may require additional evaluation for serious bacterial illness if they are febrile",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ill appearing (eg, lethargic, hypotonic, irritable). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17018?source=see_link\">",
"       \"Approach to the septic-appearing infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GAS infection &mdash; Infants, preschool, and school-aged children may develop perianal GAS infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Clinical features include a bright red, sharply demarcated perianal or perineal rash, sometimes associated with perirectal fissures, blood-streaked stools, pruritus, and pain with defecation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. Some children present with intermittent episodes of irritability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/26\">",
"       26",
"      </a>",
"      ]. The patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      household contacts may have a history of recurrent streptococcal pharyngitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/25\">",
"       25",
"      </a>",
"      ]. Treatment with antibiotics is required to improve the dermatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Herpes viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus infections may manifest with vesicular, papular, or pustular lesions in the diaper area. Herpes simplex virus infection in the diaper area is a possible manifestation of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis can appear at any age and may initially develop in the diaper area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/27\">",
"     27",
"    </a>",
"    ]. It usually presents with sharply demarcated erythematous scaly papules and plaques. Significant scale may be lacking in involved areas in the diaper region due to the presence of maceration and moisture beneath the diaper. There may be a family history of psoriasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Scabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scabies can involve the diaper region in young infants. An acute, widespread, pruritic dermatitis is the most common manifestation. Cutaneous findings include erythematous papules, nodules, and excoriations predominantly on the abdomen, web spaces of the hands and feet, axilla, and genitalia. Other family members with similar lesions and a history of pruritus support the diagnosis. Diagnosis is confirmed by identifying a mite, egg, or stool on microscopic examination of a scraping from a lesion (",
"    <a class=\"graphic graphic_picture graphicRef79567 \" href=\"mobipreview.htm?41/29/42451\">",
"     picture 3",
"    </a>",
"    ). The diagnosis and treatment of scabies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Langerhans cell histiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis (LCH) is a potentially life-threatening",
"    <span class=\"nowrap\">",
"     hematologic/oncologic",
"    </span>",
"    disorder that can present with severe or recalcitrant diaper dermatitis. The cutaneous lesions usually present during infancy or early childhood and consist of",
"    <span class=\"nowrap\">",
"     red/orange",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     yellow/brown",
"    </span>",
"    scaly papules, erosions, or petechiae most commonly in the groin, intertriginous regions, and scalp (",
"    <a class=\"graphic graphic_picture graphicRef57722 graphicRef69504 \" href=\"mobipreview.htm?38/9/39064\">",
"     picture 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LCH can resemble seborrheic dermatitis; however, the color of the lesions and presence of petechiae and erosions helps to differentiate between the two. In addition to the cutaneous findings, patients with LCH also may have bone lesions, lymphadenopathy, hepatosplenomegaly, and anemia. Skin biopsy is necessary to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child abuse is an important consideration in severe, recalcitrant, or atypical diaper dermatitis. A severe diaper dermatitis that appears \"resistant\" to treatment may actually be the result of neglect by the parent or caregiver. The diaper area also is a possible site for scalds, burns, and bruises in abused children. Although infection with the human papilloma virus (condyloma acuminatum or genital warts) in the groin region can be acquired perinatally from an infected mother, sexual abuse also should be considered and addressed as a possible underlying cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin lesions of congenital syphilis may be present at or after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. They may be seen in the diaper area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    around the mouth and nose and are characteristically copper-colored, scaly macules and papules or moist erosions; perianal papular lesions (condyloma lata) also may be seen. The skin lesions contain spirochetes and are highly infectious. Other manifestations of congenital syphilis include symmetric desquamation of the palms and soles, anemia, hepatosplenomegaly, jaundice, and changes of the long bones. The diagnosis is confirmed with serology or dark field microscopy, if available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=see_link&amp;anchor=H114346591#H114346591\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, nutritional deficiencies and immunodeficiencies can present with recalcitrant diaper dermatitis. These include acrodermatitis enteropathica (",
"    <a class=\"graphic graphic_picture graphicRef71329 \" href=\"mobipreview.htm?39/34/40481\">",
"     picture 5",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    deficiency, and cystic fibrosis (secondary to malabsorption) as well as many other uncommon disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7,29,30\">",
"     7,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IRRITANT DIAPER DERMATITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction of many inciting factors, including increased skin hydration, exposure to chemical irritants, and friction beneath the diaper, contributes to the pathogenesis of irritant diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased skin hydration develops in the diaper region because it is an occluded, moist environment. The wetness of the skin beneath the diaper increases the susceptibility to frictional damage from the diaper, which impairs normal skin barrier function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/16,31,32\">",
"     16,31,32",
"    </a>",
"    ]. An altered skin barrier then permits increased permeation of chemical irritants and microorganisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/9,16,32,33\">",
"     9,16,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary chemical irritants in the diaper area are derived from the synergistic action of urine and stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Fecal bacteria produce the enzyme urease, which interacts with urine to increase the pH level beneath the diaper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/34\">",
"     34",
"    </a>",
"    ]. Elevated pH levels activate fecal enzymes (protease and lipase) that directly irritate and damage the skin, causing an inflammatory skin eruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/35\">",
"     35",
"    </a>",
"    ]. Once the skin beneath the diaper is inflamed, microorganisms (mainly Candida albicans) are able to invade and colonize, often worsening the severity of the diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of factors may aggravate diaper dermatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with diarrhea or chronic stooling have an increased risk of developing diaper dermatitis due to continuous local skin irritation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dietary factors also may play a role. Breast-fed infants have a lower incidence of diaper dermatitis than formula-fed infants, possibly because breast-fed infants have lower stool pH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recent use of broad-spectrum antibiotics may predispose infants to develop diaper dermatitis by increasing the risk of developing diarrhea and secondary yeast infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of irritant diaper dermatitis range from asymptomatic erythema to painful scaling papules and superficial erosions. Irritant diaper dermatitis typically occurs on convex skin surfaces that are in direct contact with the diaper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These locations include the buttocks, lower abdomen, genitalia, and upper thighs. The skin folds (areas not in direct contact with the diaper) are classically spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of diaper dermatitis is focused on determining the underlying cause since the treatment varies accordingly. Atypical-appearing rashes and those that fail to resolve with conventional treatment warrant additional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Nondiaper associated'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Aspects of the history that can help identify contributing factors and support or exclude nondiaper-associated dermatitis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,22,38\">",
"     8,22,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated symptoms (eg, diarrhea).",
"     </li>",
"     <li>",
"      Systemic symptoms (may suggest nondiaper-associated dermatitis, particularly LCH).",
"     </li>",
"     <li>",
"      Information about diapers and diapering: type of diaper, how often diapers are changed, method of laundering cloth diapers (if cloth diapers are used).",
"     </li>",
"     <li>",
"      Information about how the diaper area is cleansed (eg, soaps, cleansers, washcloths, wipes, etc).",
"     </li>",
"     <li>",
"      Exposure to contagious disease (eg, scabies, herpes simplex virus, Staphylococcus aureus, group A Streptococcus).",
"     </li>",
"     <li>",
"      Past history of dermatologic, allergic, or infectious illnesses.",
"     </li>",
"     <li>",
"      Family history (eg, psoriasis, atopy).",
"     </li>",
"     <li>",
"      Antibiotic use (predisposes to candidal dermatitis and diarrhea).",
"     </li>",
"     <li>",
"      Therapies that have been used for the diaper dermatitis. It may be helpful to have caregivers bring all of the products being used in the diaper area to the office since some topical \"home remedies\" are toxic to infant skin or have the potential for systemic toxicity with percutaneous absorption (eg, boric acid, camphor, phenol, salicylates, and baking soda). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Topical barriers'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H26\">",
"       'Powders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain aspects of the examination, particularly the distribution of the rash and morphology of the lesions, help determine the etiology (",
"    <a class=\"graphic graphic_table graphicRef62319 \" href=\"mobipreview.htm?14/2/14380\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,37\">",
"     8,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory tests usually are not necessary in the evaluation of irritant diaper dermatitis. However, they may help confirm the etiology in atypical or recalcitrant cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potassium hydroxide preparation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fungal culture of skin scrapings for Candida (",
"      <a class=\"graphic graphic_picture graphicRef79879 graphicRef50344 \" href=\"mobipreview.htm?20/29/20950\">",
"       picture 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"      slide preparation for scabies (",
"      <a class=\"graphic graphic_picture graphicRef79567 \" href=\"mobipreview.htm?41/29/42451\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tzanck smear of blisters or pustules; multinucleated giant cells indicate a viral infection such as herpes simplex",
"     </li>",
"     <li>",
"      Serum zinc level for acrodermatitis enteropathica",
"     </li>",
"     <li>",
"      Culture of skin lesions for S. aureus or group A streptococcus",
"     </li>",
"     <li>",
"      Skin biopsy in cases in which the rash is atypical or unresponsive to therapy (for LCH, granuloma gluteale infantum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of irritant diaper dermatitis is made clinically. Characteristic findings include involvement of the convex surfaces and sparing of the skin folds (unless there is Candidal superinfection). The lesions may vary from asymptomatic erythema to painful scaling papules and superficial erosions. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Irritant dermatitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective way to treat irritant diaper dermatitis is to eliminate direct skin contact with urine and feces (ie, by discontinuing or limiting the use of diapers). However, in today's society, diapers are necessary to limit fecal contamination and the spread of enteric diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/11\">",
"     11",
"    </a>",
"    ]. If possible, an infant with irritant diaper dermatitis should be allowed periods of rest without a diaper, allowing the skin to be exposed directly to air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8\">",
"     8",
"    </a>",
"    ]. Frequent diaper changes limit prolonged skin contact with stool and urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Topical barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical barriers in the form of ointments or pastes are considered first-line therapy for treating and preventing irritant diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,39\">",
"     8,39",
"    </a>",
"    ]. Topical barriers are applied with every diaper change; they should be applied thickly and can be covered with petroleum jelly to prevent sticking to the diaper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of topical barrier ointments and pastes for the treatment of diaper dermatitis is based upon long-standing clinical experience; there are few randomized controlled trials comparing these agents to placebo or to one another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/39,41\">",
"     39,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical barriers physically block chemical irritants and moisture from contacting the skin; they also minimize friction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]. Topical barriers should be long-lasting and adherent to macerated and eroded skin. Pastes and ointments generally are better barriers than creams and lotions, which are poorly adherent, minimally occlusive, and contain preservatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/9,39\">",
"     9,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common over-the-counter topical barriers contain petrolatum,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    , or both (examples include Desitin, Triple Paste, A &amp; D Ointment, and Balmex) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7,8,16,22\">",
"     7,8,16,22",
"    </a>",
"    ]. Some also contain lanolin, paraffin, or dimethicone (a silicone oil) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      White petrolatum (Vaseline) is an inexpensive, hypoallergenic product that physically protects the skin.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"       Zinc oxide",
"      </a>",
"      cream, ointment, or paste is also inexpensive and provides an impermeable barrier to irritants.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"       Sucralfate",
"      </a>",
"      , a prescription medication labeled for the treatment of duodenal ulcers in the United States, also acts as a physical barrier to irritants and has antibacterial activity. Topical application of sucralfate has been reported to be useful in the management of severe or recalcitrant irritant diaper dermatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical barriers or medications that contain fragrance, preservatives, and other ingredients with irritant or allergic potential (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ) should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/39\">",
"     39",
"    </a>",
"    ]. Products containing boric acid, camphor, phenol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    , and salicylates also should be avoided because of the potential for systemic toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    methemoglobinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,17,39,43-47\">",
"     8,17,39,43-47",
"    </a>",
"    ]. These agents are contained in some commercially available products for diaper dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4841?source=see_link&amp;anchor=H11590848#H11590848\">",
"     \"Genetics and pathogenesis of methemoglobinemia\", section on 'Infants and children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Powders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of powders such as cornstarch or talcum powder is controversial. Powders can reduce friction and moisture and may be helpful in treating mild irritant diaper dermatitis; however, they pose a significant respiratory risk if accidentally aspirated and therefore are not suggested as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22,48\">",
"     22,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baking soda and boric acid powders also should be avoided because of the risk of systemic toxicity with percutaneous absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8,22,44,49\">",
"     8,22,44,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    , miconazole, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    are effective topical therapies for candidal diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/50\">",
"     50",
"    </a>",
"    ]. Antifungal agents are indicated when [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1,16,17\">",
"     1,16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dermatitis appears to be candidal (eg, beefy red plaques, satellite papules, superficial pustules; involvement of the skin folds) (",
"      <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"mobipreview.htm?35/41/36501\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Is confirmed to be candida by potassium hydroxide preparation or fungal culture (",
"      <a class=\"graphic graphic_picture graphicRef79879 graphicRef50344 \" href=\"mobipreview.htm?20/29/20950\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The dermatitis has been present for at least three days (which increases the likelihood of secondary superinfection with candida).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antifungal creams or ointments are applied to the diaper area beneath the barrier ointment at least two to three times a day until the rash has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-potency nonhalogenated topical corticosteroids (Class VII, eg, 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) may be used sparingly and cautiously for brief periods of time (ie, three to five days) to treat severely inflamed irritant diaper dermatitis. Low-potency topical corticosteroids can be applied concomitantly with barrier ointments or antimicrobial agents, including antifungal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1,2,7,9,16\">",
"     1,2,7,9,16",
"    </a>",
"    ]. When applying several topical agents, the barrier should be applied last.",
"   </p>",
"   <p>",
"    Since diapered skin is occluded, topical corticosteroids are absorbed more readily, and prolonged use is not recommended. Only the lowest potency, nonhalogenated topical corticosteroids should be prescribed; over-the-counter",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1 percent cream or ointment is often sufficient.",
"   </p>",
"   <p>",
"    Topical corticosteroids are applied twice daily for a maximum of one week's duration. Extreme caution must be used when prescribing topical corticosteroids, and if a higher potency or longer duration is required, supervision by an experienced dermatologist is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H14#H14\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Use in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination topical corticosteroids and antifungal creams such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    cream (Lotrisone) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    cream (Mycolog II) should NOT be used in the diaper area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/3,4,51,52\">",
"     3,4,51,52",
"    </a>",
"    ]. Both contain topical corticosteroids that are too potent for infant skin and may cause unwanted corticosteroid side effects such as skin atrophy and adrenal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/3,52\">",
"     3,52",
"    </a>",
"    ]. These combination creams also have been found to provide only temporary improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a secondary bacterial infection is present, topical or oral antibiotics are necessary depending upon the age of the patient. If the bacterial infection is localized and mild,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    applied topically twice a day may be sufficient to treat a staphylococcal infection; however, oral antibiotics may be necessary if the infection is moderate or severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7,11,53\">",
"     7,11,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neosporin ointment should be avoided because it contains",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , a common inciting allergen for allergic contact dermatitis. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     Bacitracin",
"    </a>",
"    ointment should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of dermatitis\", section on 'Triggers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young infants with bacterial diaper dermatitis may require additional evaluation for serious bacterial illness, especially if they are febrile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ill appearing (eg, lethargic, hypotonic, irritable). Such infants usually require hospital admission",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    initial therapy with parenteral antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17018?source=see_link\">",
"     \"Approach to the septic-appearing infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Refractory dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When diaper rash does not resolve with minimizing precipitating factors and treatment, nondiaper-associated causes of dermatitis and underlying conditions that predispose to diaper dermatitis must be considered (eg, immunodeficiency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22\">",
"     22",
"    </a>",
"    ]. Among nondiaper-associated causes of dermatitis, LCH, infections, nutritional deficiencies, and child abuse or neglect are particularly important to remember. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Nondiaper associated'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Persistent candidal diaper rash in young children may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immune deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22553?source=see_link&amp;anchor=H571998#H571998\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Clinical features of AIRE deficiency/APECED'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective way to treat irritant diaper dermatitis is to eliminate direct skin contact with urine and feces (ie, by discontinuing or limiting the use of diapers). However, in today's society, diapers are necessary to limit fecal contamination and the spread of enteric diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/11\">",
"     11",
"    </a>",
"    ]. Changing diapers frequently limits prolonged skin contact with stool and urine and is an alternate means of preventing diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Type of diaper",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is significant debate about the environmental impact of disposable versus cloth diapers, disposable diapers have been designed specifically to mitigate factors that predispose to irritant diaper dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/54-60\">",
"     54-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disposable diapers have an absorbent gel core that can absorb up to 80 times its weight in water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7,56\">",
"     7,56",
"    </a>",
"    ]. This decreases exposure of the skin to increased wetness and chemical irritants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/55\">",
"     55",
"    </a>",
"    ]. However, a systematic review of studies evaluating whether disposable diapers prevent diaper dermatitis in children concluded that there was not enough evidence from good quality randomized controlled trials to support or refute the use and type of disposable diapers to prevent diaper dermatitis in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether parents choose to use cloth or disposable diapers, frequent diaper changes help prevent irritant diaper dermatitis. During treatment of diaper dermatitis, disposable diapers may be preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Cleansing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overzealous cleansing can promote irritation and delay skin healing. Limited gentle cleansing with warm water and a soft cloth usually is sufficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7\">",
"     7",
"    </a>",
"    ]. If soaps are desired, mild soaps such as fragrance-free Dove or Cetaphil cleanser may be used.",
"   </p>",
"   <p>",
"    If the diaper area is eroded, it may be irrigated with water from a plastic squeeze bottle or by squeezing a washcloth soaked in water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22,54\">",
"     22,54",
"    </a>",
"    ]. Dried feces can be removed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    applied to a cotton ball [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/54\">",
"     54",
"    </a>",
"    ]. It is not necessary to wipe off barrier paste completely at each diaper change, but when removal is required, mineral oil is helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22,39,40,54,62\">",
"     22,39,40,54,62",
"    </a>",
"    ]. To avoid unnecessary friction, the diaper area should be dried by gently patting with a towel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22,39\">",
"     22,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, baby wipes are a common household item; however, overuse of baby wipes also may cause an irritant dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37401/abstract/2,4,16\">",
"     2,4,16",
"    </a>",
"    ]. Fragrance-free and alcohol-free baby wipes can be used sparingly but should be discontinued if the skin becomes irritated or broken down.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educating parents and caregivers in ways of preventing and treating diaper dermatitis is of utmost importance. Providing educational",
"    <span class=\"nowrap\">",
"     material/handouts",
"    </span>",
"    can be helpful since it allows families to review the information again at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/49/43793?source=see_link\">",
"       \"Patient information: Diaper rash (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/41/44690?source=see_link\">",
"       \"Patient information: Diaper rash in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diaper dermatitis is a general term that encompasses numerous skin conditions occurring in the diaper area (",
"      <a class=\"graphic graphic_table graphicRef81540 \" href=\"mobipreview.htm?35/17/36123\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of diaper dermatitis is focused on determining the underlying cause since the treatment varies accordingly. Atypical-appearing diaper rashes and those that fail to resolve with conventional treatment warrant additional evaluation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nondiaper associated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic features of irritant diaper dermatitis include involvement of the convex surfaces and sparing of the skin folds (unless there is candidal superinfection). The lesions may vary from asymptomatic erythema to painful scaling papules and superficial erosions. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest topical barrier ointments as the first-line treatment for irritant diaper dermatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Topical barriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that powders not be used as first-line treatment for irritant diaper dermatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Powders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the addition of a topical antifungal agent in children in whom the diaper dermatitis appears to be or is confirmed to be candidal, and in whom the dermatitis has been present for at least three days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Antifungal agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the addition of low-potency nonhalogenated topical corticosteroids (Class VII, eg, 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      ) for severely inflamed irritant diaper dermatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Low-potency topical corticosteroids should be applied sparingly to affected areas twice per day for a maximum of seven days; they may be used in conjunction with barrier ointments or antimicrobial agents. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using combination topical corticosteroids and antifungal creams for the treatment of irritant diaper dermatitis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest frequent diaper changes for the prevention of diaper dermatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/1\">",
"      Singalavanija S, Frieden IJ. Diaper dermatitis. Pediatr Rev 1995; 16:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/2\">",
"      Levy M. Diaper rash syndrome or dermatitis. Cutis 2001; 67:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/3\">",
"      Ward DB, Fleischer AB Jr, Feldman SR, Krowchuk DP. Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med 2000; 154:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/4\">",
"      Scheinfeld N. Diaper dermatitis: a review and brief survey of eruptions of the diaper area. Am J Clin Dermatol 2005; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/5\">",
"      Jordan WE, Lawson KD, Berg RW, et al. Diaper dermatitis: frequency and severity among a general infant population. Pediatr Dermatol 1986; 3:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/6\">",
"      Nield LS, Kamat D. Prevention, diagnosis, and management of diaper dermatitis. Clin Pediatr (Phila) 2007; 46:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/7\">",
"      Arnsmeier SL, Paller AS. Getting to the bottom of diaper dermatitis. Contemporary Pediatr 1997; 14:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/8\">",
"      Boiko S. Treatment of diaper dermatitis. Dermatol Clin 1999; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/9\">",
"      Atherton DJ. A review of the pathophysiology, prevention and treatment of irritant diaper dermatitis. Curr Med Res Opin 2004; 20:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/10\">",
"      Koblenzer PJ. Diaper dermatitis--an overview with emphasis on rational therapy based on etiology and pathodynamics. Clin Pediatr (Phila) 1973; 12:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/11\">",
"      Kazaks EL, Lane AT. Diaper dermatitis. Pediatr Clin North Am 2000; 47:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/12\">",
"      Rodriguez-Poblador J, Gonz&aacute;lez-Castro U, Herranz-Mart&iacute;nez S, Luelmo-Aguilar J. Jacquet erosive diaper dermatitis after surgery for Hirschsprung disease. Pediatr Dermatol 1998; 15:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/13\">",
"      Bluestein J, Furner BB, Phillips D. Granuloma gluteale infantum: case report and review of the literature. Pediatr Dermatol 1990; 7:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/14\">",
"      De Zeeuw R, Van Praag MC, Oranje AP. Granuloma gluteale infantum: a case report. Pediatr Dermatol 2000; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/15\">",
"      Dytoc MT, Fiorillo L, Liao J, Krol AL. Granuloma gluteale adultorum associated with use of topical benzocaine preparations: case report and literature review. J Cutan Med Surg 2002; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/16\">",
"      Wolf R, Wolf D, T&uuml;z&uuml;n B, T&uuml;z&uuml;n Y. Diaper dermatitis. Clin Dermatol 2000; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/17\">",
"      Weston WL, Lane AT, Weston JA. Diaper dermatitis: current concepts. Pediatrics 1980; 66:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/18\">",
"      Larralde M, Raspa ML, Silvia H, Lamas F. Diaper dermatitis: a new clinical feature. Pediatr Dermatol 2001; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/19\">",
"      Alberta L, Sweeney SM, Wiss K. Diaper dye dermatitis. Pediatrics 2005; 116:e450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/20\">",
"      Belhadjali H, Giordano-Labadie F, Rance F, Bazex J. \"Lucky Luke\" contact dermatitis from diapers: a new allergen? Contact Dermatitis 2001; 44:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/21\">",
"      Roul S, Ducombs G, Leaute-Labreze C, Ta&iuml;eb A. 'Lucky Luke' contact dermatitis due to rubber components of diapers. Contact Dermatitis 1998; 38:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/22\">",
"      Shin HT. Diaper dermatitis that does not quit. Dermatol Ther 2005; 18:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/23\">",
"      Brilliant LC. Perianal streptococcal dermatitis. Am Fam Physician 2000; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/24\">",
"      Kokx NP, Comstock JA, Facklam RR. Streptococcal perianal disease in children. Pediatrics 1987; 80:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/25\">",
"      Barzilai A, Choen HA. Isolation of group A streptococci from children with perianal cellulitis and from their siblings. Pediatr Infect Dis J 1998; 17:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/26\">",
"      Shouval DS, Schurr D, Nussinovitch M. Presentation of perianal group a streptococcal infection as irritability among children. Pediatr Dermatol 2008; 25:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/27\">",
"      Watanabe M, Tabata N, Tagami H. Explosive diaper pustular psoriasis. Pediatr Dermatol 2002; 19:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/28\">",
"      Atabaki S, Paradise JE. The medical evaluation of the sexually abused child: lessons from a decade of research. Pediatrics 1999; 104:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/29\">",
"      Darmstadt GL, Schmidt CP, Wechsler DS, et al. Dermatitis as a presenting sign of cystic fibrosis. Arch Dermatol 1992; 128:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/30\">",
"      Higuchi R, Mizukoshi M, Koyama H, et al. Intractable diaper dermatitis as an early sign of biotin deficiency. Acta Paediatr 1998; 87:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/31\">",
"      Berg RW, Milligan MC, Sarbaugh FC. Association of skin wetness and pH with diaper dermatitis. Pediatr Dermatol 1994; 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/32\">",
"      Stamatas GN, Zerweck C, Grove G, Martin KM. Documentation of impaired epidermal barrier in mild and moderate diaper dermatitis in vivo using noninvasive methods. Pediatr Dermatol 2011; 28:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/33\">",
"      Ferrazzini G, Kaiser RR, Hirsig Cheng SK, et al. Microbiological aspects of diaper dermatitis. Dermatology 2003; 206:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/34\">",
"      Berg RW, Buckingham KW, Stewart RL. Etiologic factors in diaper dermatitis: the role of urine. Pediatr Dermatol 1986; 3:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/35\">",
"      Buckingham KW, Berg RW. Etiologic factors in diaper dermatitis: the role of feces. Pediatr Dermatol 1986; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/36\">",
"      Honig PJ, Gribetz B, Leyden JJ, et al. Amoxicillin and diaper dermatitis. J Am Acad Dermatol 1988; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/37\">",
"      Ravanfar P, Wallace JS, Pace NC. Diaper dermatitis: a review and update. Curr Opin Pediatr 2012; 24:472.",
"     </a>",
"    </li>",
"    <li>",
"     Liptak GS. Diaper Rash. In: Primary Pediatric Care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1457.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/39\">",
"      Humphrey S, Bergman JN, Au S. Practical management strategies for diaper dermatitis. Skin Therapy Lett 2006; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/40\">",
"      Borkowski S. Diaper rash care and management. Pediatr Nurs 2004; 30:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/41\">",
"      Davies MW, Dore AJ, Perissinotto KL. Topical vitamin A, or its derivatives, for treating and preventing napkin dermatitis in infants. Cochrane Database Syst Rev 2005; :CD004300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/42\">",
"      Markham T, Kennedy F, Collins P. Topical sucralfate for erosive irritant diaper dermatitis. Arch Dermatol 2000; 136:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/43\">",
"      Farrington E. Diaper dermatitis. Pediatr Nurs 1992; 18:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/44\">",
"      Deadly diapers. Br Med J 1970; 2:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/45\">",
"      Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996; 30:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/46\">",
"      Jensen JP. [Transcutaneous absorption of boron from a baby ointment used prophylactically against diaper dermatitis]. Nord Med 1971; 86:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/47\">",
"      Tush GM, Kuhn RJ. Methemoglobinemia induced by an over-the-counter medication. Ann Pharmacother 1996; 30:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/48\">",
"      Silver P, Sagy M, Rubin L. Respiratory failure from corn starch aspiration: a hazard of diaper changing. Pediatr Emerg Care 1996; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/49\">",
"      Gonzalez J, Hogg RJ. Metabolic alkalosis secondary to baking soda treatment of a diaper rash. Pediatrics 1981; 67:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/50\">",
"      Spraker MK, Gisoldi EM, Siegfried EC, et al. Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis. Cutis 2006; 77:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/51\">",
"      Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. Pediatrics 2003; 111:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/52\">",
"      Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/53\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/54\">",
"      Boiko S. Making rash decisions in the diaper area. Pediatr Ann 2000; 29:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/55\">",
"      Odio M, Friedlander SF. Diaper dermatitis and advances in diaper technology. Curr Opin Pediatr 2000; 12:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/56\">",
"      Schuman AJ. Disposable diapers. Definitely! Contemporary Pediatr 1997; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/57\">",
"      Baldwin S, Odio MR, Haines SL, et al. Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. J Eur Acad Dermatol Venereol 2001; 15 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/58\">",
"      Odio MR, O'Connor RJ, Sarbaugh F, Baldwin S. Continuous topical administration of a petrolatum formulation by a novel disposable diaper. 2. Effect on skin condition. Dermatology 2000; 200:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/59\">",
"      Lane AT, Rehder PA, Helm K. Evaluations of diapers containing absorbent gelling material with conventional disposable diapers in newborn infants. Am J Dis Child 1990; 144:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/60\">",
"      Prasad HR, Srivastava P, Verma KK. Diapers and skin care: merits and demerits. Indian J Pediatr 2004; 71:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/61\">",
"      Baer EL, Davies MW, Easterbrook KJ. Disposable nappies for preventing napkin dermatitis in infants. Cochrane Database Syst Rev 2006; :CD004262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37401/abstract/62\">",
"      Darmstadt GL, Dinulos JG. Neonatal skin care. Pediatr Clin North Am 2000; 47:757.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5795 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37401=[""].join("\n");
var outline_f36_33_37401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diaper associated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Irritant dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Candidal dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Allergic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nondiaper associated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Seborrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Herpes viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Scabies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Child abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IRRITANT DIAPER DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Topical barriers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Powders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Refractory dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Type of diaper",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Cleansing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5795|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/26/30126\" title=\"figure 1\">",
"      Irritant diaper dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/35/41534\" title=\"figure 2\">",
"      Intertriginous diaper derm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5795|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/53/13136\" title=\"picture 1A\">",
"      Candidal diaper dermatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/53/4945\" title=\"picture 1B\">",
"      Candidal diaper dermatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/37/28242\" title=\"picture 2A\">",
"      Hyphae candida albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/12/41167\" title=\"picture 2B\">",
"      Candida albicans culture plate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/29/42451\" title=\"picture 3\">",
"      Sarcoptes scabiei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/62/34786\" title=\"picture 4A\">",
"      Langerhans histiocytosis skin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/56/4997\" title=\"picture 4B\">",
"      Langerhans histiocytosis skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/34/40481\" title=\"picture 5\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5795|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/17/36123\" title=\"table 1\">",
"      Causes diaper dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/2/14380\" title=\"table 2\">",
"      Clin features diaper derm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/41/44690?source=related_link\">",
"      Patient information: Diaper rash in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37402="Strategies for immune reconstitution following allogeneic hematopoietic cell transplantation";
var content_f36_33_37402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strategies for immune reconstitution following allogeneic hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Marcel RM van den Brink, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Jarrod A Dudakov, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/33/37402/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/33/37402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6875497\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is an important and potentially curative treatment option for a wide variety of malignant and nonmalignant diseases. Paradoxically, cytoreductive conditioning regimens designed to allow for successful allogeneic HCT are also detrimental to recovery of the immune system in general, and the production of lymphocytes in particular.",
"   </p>",
"   <p>",
"    Delayed recovery of the immune system is associated with a high degree of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Post-transplant immune depletion is particularly striking within the T cell compartment, which is exquisitely sensitive to negative regulation, evidenced by the profound decline in thymic function with age. As a consequence, regeneration of the immune system remains a significant unmet clinical need. Preclinical and clinical studies have revealed several promising therapeutic strategies to address ineffective lymphopoiesis and post-transplant immune deficiency.",
"   </p>",
"   <p>",
"    Immune reconstitution following allogeneic HCT will be discussed here. Immunization following HCT and other supportive care issues surrounding HCT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, peripheral blood progenitor cell transplantation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875504\">",
"    <span class=\"h1\">",
"     OVERVIEW OF IMMUNE RECONSTITUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical component of allogeneic HCT is the administration of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy as a conditioning (or preparative) regimen with the goal of providing adequate immunosuppression to prevent rejection of the transplanted graft. Both alkylating chemotherapeutics and irradiation target highly proliferative cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], including developing and na&iuml;ve lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, following transplant, there is severe depletion of all hematopoietic cells of the immune system, especially lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recovery of the innate (natural) and adaptive immune systems occurs gradually during the post-transplantation period. Innate immunity usually recovers over the first several months. In comparison, reconstitution of adaptive immunity takes place over the first one to two years. As described in more detail below, the timing of immune reconstitution can be affected by many variables in the transplant process, such as the particular conditioning regimen, type of donor, source of hematopoietic progenitor cells, and approach to graft-versus-host disease (GVHD) prevention. (See",
"    <a class=\"local\" href=\"#H6875541\">",
"     'Effect of transplant characteristics on immune reconstitution'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The following sections provide a general description of reconstitution of innate and adaptive immunity following transplant. A more detailed description of innate and adaptive immunity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875511\">",
"    <span class=\"h2\">",
"     Innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate (natural) immunity refers to immune responses that are present from birth and not learned, adapted, or permanently heightened as a result of exposure to microorganisms. The innate immunity is comprised of two fundamental components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nonhematopoietic compartment, which includes physical barriers such as skin and mucosal surfaces",
"     </li>",
"     <li>",
"      Hematopoietic cells including neutrophils, macrophages, as well as natural killer (NK) cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the nonhematopoietic components can be affected by the conditioning (preparative) regimens (eg, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy) used in HCT, they are usually rapidly restored following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/10\">",
"     10",
"    </a>",
"    ]. Importantly, repair of these physical barriers may be delayed by graft-versus-host disease if the skin and mucosal surfaces are involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Clinical and histological manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first hematopoietic cells to engraft following HCT are monocytes, followed by granulocytes, platelets, and NK cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/10\">",
"     10",
"    </a>",
"    ]. Neutrophil counts return to normal within two to four weeks; however, functionally they may remain suboptimal for up to four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/11\">",
"     11",
"    </a>",
"    ]. While macrophages are not significantly depleted as a result of transplant conditioning, they are gradually replaced by donor-derived macrophages over the first several months after HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/12\">",
"     12",
"    </a>",
"    ]. Functionally, monocytes may remain suboptimal for up to one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. NK cells recover both numerically and functionally within the first few weeks following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875518\">",
"    <span class=\"h2\">",
"     Adaptive immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adaptive immunity is accomplished through B and T lymphocytes that are continually refined and adjusted throughout the lifetime of the individual. Following HCT, donor-derived T and B cell lymphocytes must reconstitute the cellular and humoral immune response systems. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cellular immune response to pathogens is initiated by antigen presenting cells (eg, dendritic cells) and requires the activation of functional T cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The humoral immune response is mediated by antibodies and requires both functional B cells (plasma cells, memory cells) and T cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Full recovery of these systems can take years to achieve, especially among patients with chronic graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875527\">",
"    <span class=\"h3\">",
"     Recovery of the adaptive cellular immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following HCT, the adaptive immune system is significantly impaired largely due to the loss of na&iuml;ve T cells and the reduced function of existing T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/18-25\">",
"     18-25",
"    </a>",
"    ]. There is a reversal of the CD4:CD8 ratio with low levels of CD4 positive T cells and normal or high levels of CD8 positive T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of T cell immunity can occur via two independent routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral expansion of infused donor memory T cells leading to a narrow T cell receptor repertoire",
"     </li>",
"     <li>",
"      Seeding of the thymus by infused donor hematopoietic progenitors and subsequent generation of a diverse na&iuml;ve T cell receptor repertoire",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients receiving T cell replete grafts, peripheral expansion of infused memory T cells results in an initially narrow T cell receptor repertoire followed by expansion of the repertoire once seeding of the thymus generates na&iuml;ve T cells. This latter mechanism becomes the predominant steady-state route of T cell development and is theoretically the only mechanism of T cell recovery in T cell depleted transplants. In contrast, the former mechanism would dominate in patients without a functional thymus.",
"   </p>",
"   <p>",
"    As such, effective reconstitution of T cells following HCT requires a functional thymus, particularly in the case of CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/28\">",
"     28",
"    </a>",
"    ]. This thymic-dependence in generating an effective T cell repertoire after HCT is a critical hurdle in aging patients, where thymic atrophy is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/29\">",
"     29",
"    </a>",
"    ]. Compared with children, adults whose thymi have involuted are significantly impaired in their ability to recover following chemotherapy or HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/18,24,27,30\">",
"     18,24,27,30",
"    </a>",
"    ]. While both young and aged patients experience relatively rapid CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cell recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/31\">",
"     31",
"    </a>",
"    ], these CD8+ T cells are predominantly derived by clonal expansion that occurs outside the thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Age-related thymic involution explains why full immune recovery is possible up until middle age, whereas in older patients the peripheral na&iuml;ve T cell receptor repertoire is never fully restored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/34\">",
"     34",
"    </a>",
"    ] and infectious morbidity is directly related to low CD4 T cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6268181\">",
"     'Donor and recipient characteristics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875534\">",
"    <span class=\"h3\">",
"     Recovery of the humoral immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humoral immune response is mediated by antibodies and requires both functional B cells (plasma cells, memory cells) and T cells. In addition to the delayed recovery of T cells described above, there is also significantly impaired reconstitution in cells of the B cell lineage following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In addition to resulting in an impaired response to pathogens, an impaired humoral immune response could, theoretically, lead to disease relapse or secondary malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to T cells, B cell counts are completely depressed immediately after transplant, but reach normal levels by six months after autologous HCT and nine months after allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/41\">",
"     41",
"    </a>",
"    ]. Much like the TCR repertoire, the B cell antibody repertoire is severely diminished and suffers a prolonged recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/42\">",
"     42",
"    </a>",
"    ]. Following allogeneic HCT, this diminished B cell reconstitution is predominantly due to graft-versus-host disease (GVHD) and to medications used to treat GVHD (particularly with high-dose corticosteroids and immunosuppressants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21151647\">",
"     'Graft-versus-host disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94783236\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF RECONSTITUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general consensus that immunoglobulin titres should be routinely measured after transplantation. We and others also believe that the CD4 count should be measured at one year following HCT as an assessment of overall adaptive immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/44\">",
"     44",
"    </a>",
"    ]. Of importance, the return of lymphocyte or immunoglobulin levels to normal numbers is not always indicative of normal immune function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link&amp;anchor=H4354648#H4354648\">",
"     \"Laboratory evaluation of the immune system\", section on 'Advanced tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory evaluation of the immune system\", section on 'In vitro studies of T cell function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link&amp;anchor=H6#H6\">",
"     \"T cell receptor genetics\", section on 'T cell receptor excision circles (TRECS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no ideal marker for the assessment of immune reconstitution. Clinical studies have used one or more of the following measures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall and disease-free survival",
"     </li>",
"     <li>",
"      Clinical or culture-proven infection",
"     </li>",
"     <li>",
"      Absolute lymphocyte count",
"     </li>",
"     <li>",
"      Absolute CD4 count",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio",
"     </li>",
"     <li>",
"      T cell subset testing by flow cytometry (eg, for CD45RA, a marker of na&iuml;ve CD4+ T cells)",
"     </li>",
"     <li>",
"      Immunoglobulin levels &mdash; serum IgG levels",
"     </li>",
"     <li>",
"      Rise in antigen specific antibody titer after vaccination",
"     </li>",
"     <li>",
"      Advanced in vitro testing of B or T cell function, such as assay of mitogen-induced activation or quantification of T cell receptor rearrangement excision circles (TRECs), which correlate with newly formed antigen-specific T cells",
"     </li>",
"     <li>",
"      T cell receptor spectratyping, which allows for assessment of receptor repertoire diversity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, perhaps the most reliable marker of humoral immune reconstitution is the documentation of a clinically significant rise in antigen-specific antibodies following vaccination or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, rising CD4 counts are associated with a lower risk of infection and improved outcomes in both HCT recipients and HIV positive populations. In one study, a CD4 T cell count",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    at three months was associated with increased infections, increased non-relapse mortality, and decreased overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/45\">",
"     45",
"    </a>",
"    ]. Of importance, serum IgG levels may reflect either long-lived plasma cells that have survived the preparative regimen or B cell reconstitution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875541\">",
"    <span class=\"h1\">",
"     EFFECT OF TRANSPLANT CHARACTERISTICS ON IMMUNE RECONSTITUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, recovery of the innate and adaptive immune systems occurs gradually during the post-transplantation period. The timing of immune reconstitution can be affected by many variables in the transplant process, such as the source of stem cells, degree of human leukocyte antigen (HLA) and minor histocompatability antigen match, the conditioning regimen used and any manipulation the graft has had prior to transplant, and the presence of graft-versus-host disease. Given the complexity of the transplant process, it is impossible to quantitate the impact of any one of these factors on an individual&rsquo;s engraftment; all of these factors work in concert to affect immune reconstitution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6268181\">",
"    <span class=\"h2\">",
"     Donor and recipient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple options available in selecting a donor for an allogeneic HCT. The underlying disease, overall health of the donor and recipient, infectious history, clinical approach of the transplant center, and other factors are important in deciding what type of donor is selected. Importantly, characteristics of the donor, such as the degree of HLA-mismatch and donor age, may affect the timing of immune reconstitution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       HLA disparity",
"      </strong>",
"      &mdash; While most transplant centers prefer an HLA-matched sibling donor, it is estimated that these HLA-matched related donors are available in only approximately 25 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/46\">",
"       46",
"      </a>",
"      ]. For patients without an HLA-matched sibling, HCT can be performed using a matched unrelated donor, a single antigen mismatched related donor, a matched or mismatched umbilical cord blood unit(s), or a haploidentical donor. When compared with HCT using alternative donors, HCT using an HLA-matched related donor offers the best chance of successful immune recovery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Recipients of unrelated donor or non-HLA matched HCT have a higher rate of infectious complications than recipients of matched grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"       \"Sources of hematopoietic stem cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Donor age",
"      </strong>",
"      &mdash; Increasing donor age appears to be associated with an accumulating defect in hematopoietic stem cell function that skews the lineage potential away from lymphoid and toward myeloid precursors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/51-54\">",
"       51-54",
"      </a>",
"      ]. Moreover, hematopoietic stem cells from aged donors have been demonstrated experimentally to have reduced engraftment capacity and overall reconstitution potential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]. Consequently, increased donor age, from as young as 36 years, can affect HCT outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link&amp;anchor=H3#H3\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'Effect of donor age and other characteristics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Recipient age",
"      </strong>",
"      &mdash; Studies in mice and humans have demonstrated that, following total body irradiation and conditioning chemotherapy, there is significant damage to the thymic epithelial microenvironment resulting in reduced T cell development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/61-69\">",
"       61-69",
"      </a>",
"      ]. While previously thought to be relatively quiescent, the thymic microenvironment has been shown to be in a slow but constant flux, and to involute with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/70\">",
"       70",
"      </a>",
"      ]. Recovery of thymic function following HCT is largely dependent upon the age of the recipient. In young patients, the long term recovery of thymic function is unaffected and the epithelial compartment eventually recovers from cytoreductive therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/27,71\">",
"       27,71",
"      </a>",
"      ]. In comparison, thymic damage caused by cytoreductive conditioning can be particularly detrimental in older individuals whose thymus has already undergone significant involution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/72\">",
"       72",
"      </a>",
"      ]. Although thymic aging can be observed as early as one year old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/73\">",
"       73",
"      </a>",
"      ], significant impacts on immune reconstitution are not readily apparent until after puberty [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/27,28,74\">",
"       27,28,74",
"      </a>",
"      ]. This is discussed in more detail above. (See",
"      <a class=\"local\" href=\"#H6875527\">",
"       'Recovery of the adaptive cellular immune response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875587\">",
"    <span class=\"h2\">",
"     Source of hematopoietic stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential sources of hematopoietic stem cells used for HCT. The choice of stem cell source may affect immune reconstitution following HCT. Data regarding the impact of stem cell source on immune reconstitution largely come from retrospective studies and nonrandomized prospective trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bone marrow",
"      </strong>",
"      &mdash; The bone marrow (BM) has traditionally been the source most frequently used in HCT. Following BM infusion, innate immunity usually recovers over the first several months. In comparison, reconstitution of adaptive immunity takes place over the first one to two years. This is described in more detail above. (See",
"      <a class=\"local\" href=\"#H6875504\">",
"       'Overview of immune reconstitution'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Peripheral blood progenitor cells",
"      </strong>",
"      &mdash; Mobilized peripheral blood progenitor cells (PBPCs) have become a widely used stem cell source largely due to the convenience of peripheral collection. However, PBPC grafts contain approximately 1 log more T cells in the inoculum compared with BM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/75\">",
"       75",
"      </a>",
"      ], resulting in an increased risk of chronic graft-versus-host disease (GVHD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. While homing of BM derived stem cells is slightly better than PBPCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/78\">",
"       78",
"      </a>",
"      ], engraftment, as measured by platelet and neutrophil reconstitution, is significantly faster using PBPCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/77\">",
"       77",
"      </a>",
"      ]. This is thought to be primarily due to the relatively small number of long-term reconstituting stem cells and large number of committed multipotent progenitors seen in PBPC grafts when compared with BM grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H16#H16\">",
"       \"Sources of hematopoietic stem cells\", section on 'Relative efficacy of PBPC versus bone marrow'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Umbilical cord blood",
"      </strong>",
"      &mdash; Umbilical cord blood (UCB) is significantly enriched for hematopoietic stem cells and is used as an alternative stem cell source. One of the initial major obstacles to the widespread use of UCB for HCT was the limited quantity that can be collected from a single donor. This hurdle is at least partially overcome in adults by the transplantation of two unrelated, partially matched UCB grafts (double cord transplant) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/79\">",
"       79",
"      </a>",
"      ]. Following a double cord transplant, one of the grafts dominates long-term reconstitution while the other mediates short-term engraftment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. When compared with transplants of unrelated donor BM or mobilized PBPCs, UCB is associated with a longer median duration of neutropenia (approximately 30 versus 14 days), delayed acquired immune reconstitution, and more infectious-related morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. However, there does not appear to be an increase in infection-related death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39145?source=see_link&amp;anchor=H426439939#H426439939\">",
"       \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\", section on 'Toxicity and transplant-related mortality'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6268213\">",
"    <span class=\"h2\">",
"     Graft manipulation and cell dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;After collection, hematopoietic stem cell grafts are evaluated to determine the estimated stem cell dose. Some grafts also undergo T cell depletion or hematopoietic stem cell enrichment prior to infusion. The cell dose and graft manipulation can affect the speed of immune reconstitution following transplant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cell dose",
"      </strong>",
"      &mdash; The dose of hematopoietic stem cells infused affects the rates of hematopoietic recovery following HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/84\">",
"       84",
"      </a>",
"      ]. The dose required for rapid and stable long-term engraftment varies depending upon the method of measurement and the source of stem cells. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H6#H6\">",
"       \"Sources of hematopoietic stem cells\", section on 'Bone marrow'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H10#H10\">",
"       \"Sources of hematopoietic stem cells\", section on 'Optimal CD34 cell dose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604500#H61604500\">",
"       \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cell dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       T cell depletion",
"      </strong>",
"      &mdash; Some centers use T cell depletion or hematopoietic stem cell enrichment to manipulate the stem cell graft in an effort to decrease rates of graft-versus-host disease (GVHD). While these techniques are effective in preventing acute GVHD across both major and minor histocompatibility barriers, removal of T cells from donor bone marrow may adversely affect engraftment, the adequacy of immune reconstitution, and the incidence of leukemic relapse or infections. T cell depletion of the allograft leads to significantly delayed immune reconstitution and causes increased morbidity and mortality from infection in both younger and older recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/85-87\">",
"       85-87",
"      </a>",
"      ]. Conversely, several small studies have demonstrated that a higher number of regulatory T cells (Tregs) in the graft is associated with improved immune reconstitution and reduced GVHD and cytomegalovirus infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/88-91\">",
"       88-91",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=see_link\">",
"       \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875594\">",
"    <span class=\"h2\">",
"     Conditioning and immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conditioning (or preparative) regimen is designed to provide adequate immunosuppression to prevent rejection of the transplanted graft. There are many different conditioning regimens that utilize chemotherapeutic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total body irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/47\">",
"     47",
"    </a>",
"    ]. Murine models have demonstrated that the use of higher intensity conditioning regimens can significantly enhance the engraftment of unrelated mismatched grafts, but also increase treatment-associated toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditioning regimens have been termed myeloablative, reduced intensity, and nonmyeloablative. While full agreement has not been achieved, definitions of these three types of conditioning regimens have been proposed. A myeloablative regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia. The resulting pancytopenia is long-lasting, likely irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. In comparison, host hematopoietic recovery is not fully eliminated following reduced intensity or nonmyeloablative conditioning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H2#H2\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Preparative regimen intensity defined'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described above, the thymus is responsible for the generation of a diverse na&iuml;ve T cell receptor repertoire. Following HCT, the thymus is seeded by infused donor hematopoietic progenitors, which are important for reconstituting the adaptive cellular immune response. While myeloablative, reduced intensity, and nonmyeloablative conditioning regimens can damage the thymus, it is not known whether the degree of thymic damage varies by conditioning intensity. The kinetics of immune reconstitution following nonmyeloablative conditioning have not been as well defined but suggest faster early recovery than with myeloablative conditioning, though with similar rate of recovery of late immune functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also of considerable interest is the impact of conditioning regimens, both for HCT engraftment and for stem cell mobilization, on hematopoietic stem cell function. While quiescent hematopoietic stem cells are largely numerically spared from many chemotherapeutic and low-dose radiation regimes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/93\">",
"     93",
"    </a>",
"    ], their hematopoietic function appears to be significantly impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Such cells appear to exhibit enhanced senescence coupled with an upregulation in the cyclin-depending kinase inhibitors p19",
"    <sup>",
"     Arf",
"    </sup>",
"    and p16",
"    <sup>",
"     ink4A",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], mimicking some of the effects seen with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21151647\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune",
"    <strong>",
"    </strong>",
"    reconstitution is significantly delayed by acute and chronic graft-versus-host disease (GVHD) and its therapy. The traditional description of chronic GVHD on the basis of time of onset (ie, after day 100 of HCT) has been replaced by emphasis on pathobiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/98\">",
"     98",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Indeed, the clinical features consistent with chronic GVHD may be present as early as 50 days after HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/98\">",
"     98",
"    </a>",
"    ], and manifestations of acute GVHD may not develop until several months, particularly after nonmyeloablative conditioning, and may even overlap with the manifestations of chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/99\">",
"     99",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GVHD can affect the skin and mucosal surfaces that comprise the nonhematopoietic compartment of the innate (natural) immune system. Damage to these areas from the conditioning regimen is usually rapidly reversed following HCT. However, repair of these physical barriers may be delayed by graft-versus-host disease if the skin and mucosal surfaces are involved.",
"   </p>",
"   <p>",
"    Patients with chronic GVHD have significant defects in both humoral and cell-mediated immunity, delayed reconstitution of antigen presenting cells, and functional hyposplenism. Patients with acute GVHD can have lower plasma and dendritic cell nadir counts due to a graft-versus-host plasma",
"    <span class=\"nowrap\">",
"     cell/Langerhans",
"    </span>",
"    cell effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/10,100\">",
"     10,100",
"    </a>",
"    ]. Recovery of monocyte function can take up to one year, while the number and function of tissue dendritic cells (eg, Langerhans cells) can take up to six months. Immune reconstitution and response to vaccines can be further hindered by the use of systemic corticosteroids and other immunosuppressants to treat chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/101\">",
"     101",
"    </a>",
"    ]. In addition, the thymus has also been shown to be extremely sensitive to the treatments used to suppress the immune system from the impacts of GVHD, as well as GVHD itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/102-106\">",
"     102-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875601\">",
"    <span class=\"h1\">",
"     THERAPEUTIC STRATEGIES TO IMPROVE IMMUNE RECONSTITUTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6155646\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been proposed to enhance immune reconstitution following HCT. While many have been studied in preclinical settings, only a few have been translated to the clinic. Proposed strategies include the exogenous administration of cytokines and hormones (eg, keratinocyte growth factor, IL-7), sex steroid ablation (SSA), infusion of precursor lymphoid cells, and the creation of ectopic thymus tissue. Crosstalk between the thymic stroma and the hematopoietic compartment suggests that a combination of strategies targeting different compartments contributing towards thymopoiesis will lead to a greater regenerative boost than could be achieved with any single strategy alone. These strategies are described in the following sections.",
"   </p>",
"   <p>",
"    Successful combinations are likely to be those that combine strategies targeting different pathways. As an example, it has been proposed that keratinocyte growth factor (KGF) may be successfully combined with precursor lymphocyte infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/107\">",
"     107",
"    </a>",
"    ], sex steroid ablation (SSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/67\">",
"     67",
"    </a>",
"    ], and temporary inhibition of p53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, it is unlikely that IL-7 could be used effectively in combination with KGF or SSA to promote thymopoiesis, as both of these strategies promote intrathymic production of IL-7, and studies in knockout mice demonstrate that both of these regenerative strategies are dependent on IL-7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interaction between developing T cells and the supporting thymic stromal microenvironment is critical for normal thymus function, and has been exploited to great effect for thymic regeneration. However, the fundamental relationship between the bone marrow and the thymus, which is primarily predicated on the supply of lymphoid precursors, has been far less explored as a means for promoting immune regeneration. While the precise identity of the circulating progenitor released from the bone marrow to seed the thymus is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/110-114\">",
"     110-114",
"    </a>",
"    ], the potential for improving immune reconstitution is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/115\">",
"     115",
"    </a>",
"    ]. Fundamental defects in hematopoietic stem cell function, particularly in their ability to differentiate down the lymphoid lineage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/116\">",
"     116",
"    </a>",
"    ], may contribute towards some of the age-related changes observed in the thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/117\">",
"     117",
"    </a>",
"    ]. However, at least in studies of age-related thymic hypoplasia, improvement of stem cell function alone is not sufficient to restore thymopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/118\">",
"     118",
"    </a>",
"    ] and the reduced importation of progenitors is not enough to cause thymic involution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/119\">",
"     119",
"    </a>",
"    ]. This suggests that these defects in hematopoietic stem cell function merely contribute to, rather than cause, age-related declines in lymphopoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875610\">",
"    <span class=\"h2\">",
"     Cytokines and hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been proposed to enhance immune reconstitution following HCT. While many have been studied in preclinical settings, only a few have been translated to the clinic. Proposed strategies have included the exogenous administration of cytokines and hormones identified by their ability to regenerate lymphopoiesis in model systems. Of these, keratinocyte growth factor (KGF), IL-7, Flt-3 ligand (Flt3L), and growth hormone (GH) have all shown promise in their regenerative abilities.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Keratinocyte growth factor",
"      </strong>",
"      &mdash; In animal models, exogenous administration of KGF has been found to increase thymic cellularity up to fourfold in the aged and following radiation or chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/108,120,121\">",
"       108,120,121",
"      </a>",
"      ]. Furthermore, KGF can protect thymic epithelial cells (TECs) from graft-versus-host disease-mediated thymic damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/121\">",
"       121",
"      </a>",
"      ], and KGF-induced thymopoiesis is mediated by proliferation and expansion of TECs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/122\">",
"       122",
"      </a>",
"      ]. While KGF has been approved by the US Food and Drug Administration for the prophylaxis of mucositis in recipients of high dose chemotherapy (including HCT), no clinical data exist regarding the potential of KGF to enhance T cell reconstitution in patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       IL-7",
"      </strong>",
"      &mdash; The pro-lymphopoietic cytokine IL-7 can act directly on T-lymphoid precursors and has been shown in several studies to enhance thymopoiesis. IL-7 appears to affect recent thymic emigrants and improve peripheral T cell function in aged mice and following allogeneic HCT in animal models [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/123-127\">",
"       123-127",
"      </a>",
"      ]. IL7 appears to induce thymic regeneration by reversing age-related increases in apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/128\">",
"       128",
"      </a>",
"      ], while simultaneously enhancing the proliferation of lymphocytes and lymphoid precursors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/123\">",
"       123",
"      </a>",
"      ]. Administration of IL-7 in both animal models and humans has resulted in T cell proliferation, increased T cell numbers, and increased T cell receptor diversity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/129\">",
"       129",
"      </a>",
"      ]. A phase I trial of recombinant IL-7 in 12 adults undergoing T cell depleted allogeneic HCT suggested that this approach improved T cell recovery and T cell repertoire diversity without increased graft-versus-host disease or other toxicities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Flt3L",
"      </strong>",
"      &mdash; Preclinical studies have shown that exogenous Flt3L enhances both thymic dependent and independent T cell reconstitution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/131,132\">",
"       131,132",
"      </a>",
"      ]. The effects of Flt3L are predominantly due to an expansion in Flt3",
"      <sup>",
"       +",
"      </sup>",
"      progenitors in the bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/133\">",
"       133",
"      </a>",
"      ]. However, increases in T cell reconstitution can be at the expense of B-lymphopoiesis. Generation of B lymphocytes, in general, and early progenitors with lymphoid and myeloid potential, in particular, is significantly lower following the administration of exogenous Flt3L [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/134,135\">",
"       134,135",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Growth hormone",
"      </strong>",
"      &mdash; Treatment with exogenous GH regenerates the aged thymus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/136,137\">",
"       136,137",
"      </a>",
"      ] and enhances hematopoietic cell function in the bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/138\">",
"       138",
"      </a>",
"      ]. GH has also been shown to reverse irradiation-associated loss of bone marrow function determined by colony formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/138\">",
"       138",
"      </a>",
"      ]. While the clinical experience with GH and T cell recovery is limited to studies in patients with HIV, it has been demonstrated to significantly enhance thymus function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/139-141\">",
"       139-141",
"      </a>",
"      ] and anti-viral responses in this population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/139-142\">",
"       139-142",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other cytokines and growth factors have been evaluated in this setting. IGF-1 promotes thymic endothelial cell expansion and enhances reconstitution following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/143-145\">",
"     143-145",
"    </a>",
"    ]. IL-2 increases the number and function of regulatory T (Treg) cells and decreases clinical manifestations of chronic graft-versus-host disease among HCT recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/146\">",
"     146",
"    </a>",
"    ]. IL-15 predominantly promotes proliferation of circulating NK and T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/147,148\">",
"     147,148",
"    </a>",
"    ]. IL-12 stimulates thymic expression of IL-7 and enhances hematopoietic engraftment after transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/149-151\">",
"     149-151",
"    </a>",
"    ]. IL-15 and IL-12 have also been found to activate regulatory lymphoid-tissue inducer cells and NK cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Parathyroid hormone (PTH) can enhance hematopoietic stem cell numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/154\">",
"     154",
"    </a>",
"    ] and retinoic acid accelerates B lymphopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875652\">",
"    <span class=\"h2\">",
"     Sex steroid ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen and testosterone have been implicated in the regulation of thymopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/156,157\">",
"     156,157",
"    </a>",
"    ], B-lymphopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/158-160\">",
"     158-160",
"    </a>",
"    ], and the generation of early lymphoid precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/161,162\">",
"     161,162",
"    </a>",
"    ]. Interest in the use of sex steroid ablation (SSA) to enhance immune reconstitution was initially born from animal studies that demonstrated improved thymic function following castration or chemical androgen blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/163,164\">",
"     163,164",
"    </a>",
"    ]. Subsequently, SSA has been investigated for its potential in enhancing the immune system following HCT.",
"   </p>",
"   <p>",
"    Removal of sex steroids in aged mice and humans leads to reorganized thymic architecture and transport of circulating progenitors into the thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/165\">",
"     165",
"    </a>",
"    ], and subsequently enhances",
"    <strong>",
"    </strong>",
"    thymopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/61,72,163-169\">",
"     61,72,163-169",
"    </a>",
"    ]. The effects of SSA, however, are not restricted to the thymus and include enhanced B-lymphopoiesis and an increase in lymphoid progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/117,170-174\">",
"     117,170-174",
"    </a>",
"    ], as well as enhanced overall immune recovery following autologous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/175\">",
"     175",
"    </a>",
"    ] and allogeneic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/109\">",
"     109",
"    </a>",
"    ] HCT, as well as cytoablative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/61,72,174\">",
"     61,72,174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that SSA may improve immune reconstitution following HCT. As of yet, experimental and clinical data are largely limited to the use of luteinizing hormone releasing hormone (LHRH) analogues or surgical ablation. More advanced LHRH antagonists result in almost immediate cessation of sex steroid production and subsequently significantly shorter time to sex steroid ablation. Further study is warranted prior to its widespread application. Androgen deprivation is commonly employed in the treatment of patients with prostate cancer. Side effects of androgen deprivation are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875659\">",
"    <span class=\"h2\">",
"     Cellular therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875667\">",
"    <span class=\"h3\">",
"     Precursor lymphoid cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental studies suggest that lymphoid precursor cells can be isolated from donor bone marrow and infused into the recipient at the time of allogeneic HCT to boost T cell development following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/115\">",
"     115",
"    </a>",
"    ]. These precursor T cell populations can be expanded using ex vivo culture systems that use Notch-1 stimulation of hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/107,176-178\">",
"     107,176-178",
"    </a>",
"    ]. Importantly, precursor T cells can be transferred across major histocompatibility barriers and develop into host-tolerant and fully competent T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preclinical studies, adoptive transfer of T cell precursors into lethally irradiated allogeneic HCT recipients caused significant increases in thymic cellularity and chimerism, as well as enhanced peripheral T and NK cell reconstitution compared with recipients of allogeneic hematopoietic stem cells only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/107,180,181\">",
"     107,180,181",
"    </a>",
"    ]. In addition to the significant benefit for immune regeneration following transplant, in vitro generated pre-T cells can also be genetically engineered for tumor-specificity and subsequently used for targeted tumor immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of donor lymphocyte infusions and other adoptive cell therapies as immunotherapy for the prevention and treatment of relapse (or infections) following HCT is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875674\">",
"    <span class=\"h3\">",
"     Artificial organs and bioreactors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic tissue transplant has been used for the treatment of infants with congenital hypoplastic thymus (eg, DiGeorge syndrome), but is limited by the scarcity of thymic donor tissue. While efforts to create an ectopic thymus are underway, this approach is still in early phases of development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15608?source=see_link&amp;anchor=H23#H23\">",
"     \"DiGeorge syndrome: Management and prognosis\", section on 'Cultured thymic transplant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several groups are attempting to identify and isolate populations of thymic epithelial progenitor cells (TEPC) that could be used to directly enhance the function of the thymus by providing regenerative benefit to the supporting stromal microenvironment. While using different strategies, TEPC have been successfully isolated from fetal thymi and coaxed into generating a new thymus in",
"    <span class=\"nowrap\">",
"     FoxN1",
"     <sup>",
"      -/-",
"     </sup>",
"    </span>",
"    recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/182-185\">",
"     182-185",
"    </a>",
"    ]; the identity and existence of a similar population in the adult thymus have thus far remained elusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/186,187\">",
"     186,187",
"    </a>",
"    ]. However, one study has directed the reprogramming of thymic epithelial cells into functional multipotent skin stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/188\">",
"     188",
"    </a>",
"    ]. A reverse of this approach, by reprogramming skin epithelium into TEPC, would offer an excellent opportunity to either regenerate the thymus by grafting TEPC directly or even ex vivo generation of a transplantable thymus.",
"   </p>",
"   <p>",
"    There are also several approaches to rejuvenate immunity being considered that do not rely on the endogenous thymus at all, but rather concentrate on forming whole organs ex vivo that can be transplanted into patients as required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/189,190\">",
"     189,190",
"    </a>",
"    ]. One such approach removes the cells in an existing organ, leaving only the extracellular matrix components, and rebuilds the organ using biomatrices in addition to vascularizing chambers. Critically, this approach removes the significant immune barriers preventing xenogenic transplantation. This technique has so far been achieved in heart, liver, and lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/191-194\">",
"     191-194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, an ectopic thymus might be generated ex vivo using TEPC and mesenchymal elements to seed biomatrices. One study, which used this approach in combination with implantable chambers that promote vascularization, was able to generate a functional thymus in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/33/37402/abstract/195\">",
"     195",
"    </a>",
"    ]. However, at this stage these approaches still require TEPC to initiate thymic organogenesis highlighting the dependence of fetal tissue and the importance of discovering an adult TEPC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6875688\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recovery of the innate (natural) and adaptive immune systems occurs gradually following allogeneic hematopoietic cell transplantation (HCT). Innate immunity usually recovers over the first several months. In comparison, reconstitution of adaptive immunity takes place over the first one to two years. (See",
"      <a class=\"local\" href=\"#H6875504\">",
"       'Overview of immune reconstitution'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nonhematopoietic components of the innate immune system (eg, skin and mucosal linings) are damaged by the preparative regimen (eg, chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy), but are usually restored rapidly following HCT. Repair of these physical barriers may be delayed by graft-versus-host disease if the skin and mucosal surfaces are involved. (See",
"      <a class=\"local\" href=\"#H6875511\">",
"       'Innate immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The hematopoietic components of the innate immune system (ie, monocytes, granulocytes, natural killer cells) usually recover over the first several months. Neutrophil counts return to normal within two to four weeks; however, functionally they may remain suboptimal for up to four months. While macrophages are not significantly depleted as a result of transplant conditioning, they are gradually replaced by donor-derived macrophages over the first several months, and functionally may remain suboptimal for up to one year. Natural killer cells recover both numerically and functionally within the first weeks after transplant. (See",
"      <a class=\"local\" href=\"#H6875511\">",
"       'Innate immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The adaptive immune system is significantly impaired following HCT largely due to the loss of na&iuml;ve T cells and the reduced function of existing T cells. There is a reversal of the CD4:CD8 ratio. Recovery of T cell immunity occurs via the peripheral expansion of infused donor memory T cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seeding of the thymus by infused donor hematopoietic progenitors. B cell counts reach normal levels by nine months after HCT. Both the T cell receptor and B cell antibody repertoires are severely diminished and suffer prolonged recoveries. (See",
"      <a class=\"local\" href=\"#H6875518\">",
"       'Adaptive immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The timing of immune reconstitution can be affected by many variables in the transplant process, including the source of stem cells, degree of human leukocyte antigen (HLA) match, the conditioning regimen used, manipulation of graft prior to transplant, and the presence of graft-versus-host disease. Given the complexity of the transplant process, it is impossible to quantitate the impact of any one of these factors on an individual&rsquo;s engraftment; all of these factors work in concert to affect immune reconstitution. (See",
"      <a class=\"local\" href=\"#H6875541\">",
"       'Effect of transplant characteristics on immune reconstitution'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A number of strategies have been proposed to enhance immune reconstitution following HCT. While many have been studied in preclinical settings, only a few have been translated to the clinic. (See",
"      <a class=\"local\" href=\"#H6875601\">",
"       'Therapeutic strategies to improve immune reconstitution'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/1\">",
"      Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/2\">",
"      Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. II. Nonbacterial infections. J Pediatr 1991; 119:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/3\">",
"      Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/4\">",
"      Brock N. The history of the oxazaphosphorine cytostatics. Cancer 1996; 78:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/5\">",
"      Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/6\">",
"      Trobaugh FE Jr, Husseini S. Effects of radiation on hematopoietic tissue. Am J Med Technol 1973; 39:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/7\">",
"      Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol 2010; 88:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/8\">",
"      Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, et al. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/9\">",
"      Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 2006; 12:4203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/10\">",
"      Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008; 30:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/11\">",
"      Zimmerli W, Zarth A, Gratwohl A, Speck B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood 1991; 77:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/12\">",
"      Nakata K, Gotoh H, Watanabe J, et al. Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation. Blood 1999; 93:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/13\">",
"      Cayeux S, Meuer S, Pezzutto A, et al. Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogeneous IL-2. Blood 1989; 74:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/14\">",
"      Sahdev I, O'Reilly R, Black P, et al. Interleukin-1 production following T-cell-depleted and unmodified marrow grafts. Pediatr Hematol Oncol 1996; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/15\">",
"      Hokland M, Jacobsen N, Ellegaard J, Hokland P. Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation 1988; 45:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/16\">",
"      Jacobs R, Stoll M, Stratmann G, et al. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992; 79:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/17\">",
"      Vitale C, Pitto A, Benvenuto F, et al. Phenotypic and functional analysis of the HLA-class I-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors. Hematol J 2000; 1:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/18\">",
"      Weinberg K, Annett G, Kashyap A, et al. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant 1995; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/19\">",
"      Roux E, Helg C, Dumont-Girard F, et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87:3984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/20\">",
"      Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998; 92:4464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/21\">",
"      Ault KA, Antin JH, Ginsburg D, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 1985; 161:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/22\">",
"      Gratama JW, Naipal A, Oljans P, et al. T lymphocyte repopulation and differentiation after bone marrow transplantation. Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood 1984; 63:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/23\">",
"      Roosnek EE, Brouwer MC, Vossen JM, et al. The role of interleukin-2 in proliferative responses in vitro of T cells from patients after bone marrow transplantation. Evidence that minor defects can lead to in vitro unresponsiveness. Transplantation 1987; 43:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/24\">",
"      Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000; 96:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/25\">",
"      Soiffer RJ, Bosserman L, Murray C, et al. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990; 75:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/26\">",
"      Atkinson K, Hansen JA, Storb R, et al. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood 1982; 59:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/27\">",
"      Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/28\">",
"      Hakim FT, Memon SA, Cepeda R, et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005; 115:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/29\">",
"      Rodewald HR. The thymus in the age of retirement. Nature 1998; 396:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/30\">",
"      Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/31\">",
"      Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/32\">",
"      Fagnoni FF, Lozza L, Zibera C, et al. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology 2002; 106:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/33\">",
"      Heitger A, Neu N, Kern H, et al. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood 1997; 90:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/34\">",
"      Sfikakis PP, Gourgoulis GM, Moulopoulos LA, et al. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest 2005; 35:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/35\">",
"      Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/36\">",
"      Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96:3290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/37\">",
"      Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 2005; 35 Suppl 1:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/38\">",
"      MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/39\">",
"      von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/40\">",
"      White CA, Weaver RL, Grillo-L&oacute;pez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/41\">",
"      Storek J. B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/42\">",
"      Li F, Jin F, Freitas A, et al. Impaired regeneration of the peripheral B cell repertoire from bone marrow following lymphopenia in old mice. Eur J Immunol 2001; 31:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/43\">",
"      Storek J, Wells D, Dawson MA, et al. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/44\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/45\">",
"      Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/46\">",
"      Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115:3861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/47\">",
"      Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/48\">",
"      Hamza NS, Lisgaris M, Yadavalli G, et al. Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults. Br J Haematol 2004; 124:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/49\">",
"      van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002; 30:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/50\">",
"      Yoo JH, Lee DG, Choi SM, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2004; 34:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/51\">",
"      Guerrettaz LM, Johnson SA, Cambier JC. Acquired hematopoietic stem cell defects determine B-cell repertoire changes associated with aging. Proc Natl Acad Sci U S A 2008; 105:11898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/52\">",
"      Muller-Sieburg CE, Cho RH, Karlsson L, et al. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood 2004; 103:4111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/53\">",
"      Signer RA, Montecino-Rodriguez E, Witte ON, et al. Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia. Blood 2007; 110:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/54\">",
"      Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 2005; 102:9194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/55\">",
"      Kamminga LM, van Os R, Ausema A, et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells 2005; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/56\">",
"      Kim M, Moon HB, Spangrude GJ. Major age-related changes of mouse hematopoietic stem/progenitor cells. Ann N Y Acad Sci 2003; 996:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/57\">",
"      Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 2005; 106:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/58\">",
"      Carreras E, Jim&eacute;nez M, G&oacute;mez-Garc&iacute;a V, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/59\">",
"      Harrison DE, Astle CM. Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. J Exp Med 1982; 156:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/60\">",
"      Mehta J, Gordon LI, Tallman MS, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant 2006; 38:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/61\">",
"      Goldberg GL, Dudakov JA, Reiseger JJ, et al. Sex steroid ablation enhances immune reconstitution following cytotoxic antineoplastic therapy in young mice. J Immunol 2010; 184:6014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/62\">",
"      Fredrickson GG, Basch RS. Early thymic regeneration after irradiation. Dev Comp Immunol 1994; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/63\">",
"      Hauri-Hohl MM, Zuklys S, Keller MP, et al. TGF-beta signaling in thymic epithelial cells regulates thymic involution and postirradiation reconstitution. Blood 2008; 112:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/64\">",
"      Popa I, Zubkova I, Medvedovic M, et al. Regeneration of the adult thymus is preceded by the expansion of K5+K8+ epithelial cell progenitors and by increased expression of Trp63, cMyc and Tcf3 transcription factors in the thymic stroma. Int Immunol 2007; 19:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/65\">",
"      Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99:4592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/66\">",
"      Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood 2001; 98:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/67\">",
"      Kelly RM, Highfill SL, Panoskaltsis-Mortari A, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood 2008; 111:5734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/68\">",
"      Kelly RM, Goren EM, Taylor PA, et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood 2010; 115:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/69\">",
"      Williams KM, Mella H, Lucas PJ, et al. Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin Transl Sci 2009; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/70\">",
"      Gray DH, Seach N, Ueno T, et al. Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. Blood 2006; 108:3777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/71\">",
"      Sykes M, Szot GL, Swenson K, et al. Separate regulation of peripheral hematopoietic and thymic engraftment. Exp Hematol 1998; 26:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/72\">",
"      Dudakov JA, Goldberg GL, Reiseger JJ, et al. Sex steroid ablation enhances hematopoietic recovery following cytotoxic antineoplastic therapy in aged mice. J Immunol 2009; 183:7084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/73\">",
"      Flores KG, Li J, Sempowski GD, et al. Analysis of the human thymic perivascular space during aging. J Clin Invest 1999; 104:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/74\">",
"      Savage WJ, Bleesing JJ, Douek D, et al. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant 2001; 28:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/75\">",
"      Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/76\">",
"      Russell NH, Gratwohl A, Schmitz N. Developments in allogeneic peripheral blood progenitor cell transplantation. Br J Haematol 1998; 103:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/77\">",
"      K&ouml;rbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/78\">",
"      Szilvassy SJ, Meyerrose TE, Ragland PL, Grimes B. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood 2001; 98:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/79\">",
"      Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/80\">",
"      Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011; 117:3277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/81\">",
"      Gutman JA, Turtle CJ, Manley TJ, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 2010; 115:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/82\">",
"      Delaney C, Gutman JA, Appelbaum FR. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009; 147:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/83\">",
"      Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009; 147:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/84\">",
"      Chen BJ, Cui X, Sempowski GD, et al. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004; 103:4344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/85\">",
"      Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009; 113:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/86\">",
"      Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007; 109:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/87\">",
"      M&uuml;ller SM, Kohn T, Schulz AS, et al. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 2000; 96:4344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/88\">",
"      Torelli GF, Lucarelli B, Iori AP, et al. The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection. Leuk Res 2011; 35:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/89\">",
"      Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/90\">",
"      Gaidot A, Landau DA, Martin GH, et al. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood 2011; 117:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/91\">",
"      Winstead CJ, Reilly CS, Moon JJ, et al. CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J Immunol 2010; 184:4749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/92\">",
"      Soderling CC, Song CW, Blazar BR, Vallera DA. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants. J Immunol 1985; 135:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/93\">",
"      Gardner RV, McKinnon E, Astle CM. Analysis of the stem cell sparing properties of cyclophosphamide. Eur J Haematol 2001; 67:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/94\">",
"      Gardner RV, McKinnon E, Poretta C, Leiva L. Hemopoietic function after use of IL-1 with chemotherapy or irradiation. J Immunol 2003; 171:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/95\">",
"      Meng A, Wang Y, Brown SA, et al. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol 2003; 31:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/96\">",
"      Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res 2003; 63:5414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/97\">",
"      Wang Y, Schulte BA, LaRue AC, et al. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 2006; 107:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/98\">",
"      Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/99\">",
"      Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.",
"     </a>",
"    </li>",
"    <li>",
"     Keever-Taylor. Immune reconstitution after allogeneic transplantation. In: Hematopoietic Stem Cell Transplantation, Soiffer RJ.  (Ed), Humana Press, Totowa, New Jersey 2008. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/101\">",
"      Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/102\">",
"      Fletcher AL, Lowen TE, Sakkal S, et al. Ablation and regeneration of tolerance-inducing medullary thymic epithelial cells after cyclosporine, cyclophosphamide, and dexamethasone treatment. J Immunol 2009; 183:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/103\">",
"      Purton JF, Monk JA, Liddicoat DR, et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 2004; 173:3816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/104\">",
"      Na IK, Lu SX, Yim NL, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest 2010; 120:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/105\">",
"      Krenger W, Holl&auml;nder GA. The immunopathology of thymic GVHD. Semin Immunopathol 2008; 30:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/106\">",
"      Krenger W, Rossi S, Holl&auml;nder GA. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation 2000; 69:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/107\">",
"      Zakrzewski JL, Kochman AA, Lu SX, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006; 12:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/108\">",
"      Alpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood 2006; 107:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/109\">",
"      Goldberg GL, Alpdogan O, Muriglan SJ, et al. Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. J Immunol 2007; 178:7473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/110\">",
"      Wada H, Masuda K, Satoh R, et al. Adult T-cell progenitors retain myeloid potential. Nature 2008; 452:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/111\">",
"      Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/112\">",
"      Schwarz BA, Bhandoola A. Circulating hematopoietic progenitors with T lineage potential. Nat Immunol 2004; 5:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/113\">",
"      Serwold T, Ehrlich LI, Weissman IL. Reductive isolation from bone marrow and blood implicates common lymphoid progenitors as the major source of thymopoiesis. Blood 2009; 113:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/114\">",
"      Martin CH, Aifantis I, Scimone ML, et al. Efficient thymic immigration of B220+ lymphoid-restricted bone marrow cells with T precursor potential. Nat Immunol 2003; 4:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/115\">",
"      Arber C, BitMansour A, Sparer TE, et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2003; 102:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/116\">",
"      Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol 2009; 30:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/117\">",
"      Dudakov JA, Khong DM, Boyd RL, Chidgey AP. Feeding the fire: the role of defective bone marrow function in exacerbating thymic involution. Trends Immunol 2010; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/118\">",
"      Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997; 160:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/119\">",
"      Gui J, Zhu X, Dohkan J, et al. The aged thymus shows normal recruitment of lymphohematopoietic progenitors but has defects in thymic epithelial cells. Int Immunol 2007; 19:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/120\">",
"      Min D, Panoskaltsis-Mortari A, Kuro-O M, et al. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 2007; 109:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/121\">",
"      Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002; 100:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/122\">",
"      Rossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood 2007; 109:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/123\">",
"      Alpdogan O, Muriglan SJ, Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest 2003; 112:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/124\">",
"      Lu H, Zhao Z, Kalina T, et al. Interleukin-7 improves reconstitution of antiviral CD4 T cells. Clin Immunol 2005; 114:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/125\">",
"      Sempowski GD, Gooding ME, Liao HX, et al. T cell receptor excision circle assessment of thymopoiesis in aging mice. Mol Immunol 2002; 38:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/126\">",
"      Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/127\">",
"      Chu YW, Memon SA, Sharrow SO, et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004; 104:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/128\">",
"      Andrew D, Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 2001; 166:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/129\">",
"      Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/130\">",
"      Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012; 120:4882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/131\">",
"      Fry TJ, Sinha M, Milliron M, et al. Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood 2004; 104:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/132\">",
"      Kenins L, Gill JW, Boyd RL, et al. Intrathymic expression of Flt3 ligand enhances thymic recovery after irradiation. J Exp Med 2008; 205:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/133\">",
"      Wils EJ, Braakman E, Verjans GM, et al. Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation. J Immunol 2007; 178:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/134\">",
"      Balciunaite G, Ceredig R, Massa S, Rolink AG. A B220+ CD117+ CD19- hematopoietic progenitor with potent lymphoid and myeloid developmental potential. Eur J Immunol 2005; 35:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/135\">",
"      Ceredig R, Rauch M, Balciunaite G, Rolink AG. Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood 2006; 108:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/136\">",
"      Dixit VD, Yang H, Sun Y, et al. Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007; 117:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/137\">",
"      Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev 2005; 205:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/138\">",
"      Carlo-Stella C, Di Nicola M, Milani R, et al. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Exp Hematol 2004; 32:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/139\">",
"      Herasimtschuk AA, Westrop SJ, Moyle GJ, et al. Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines 2008; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/140\">",
"      Napolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008; 118:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/141\">",
"      Napolitano LA, Lo JC, Gotway MB, et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/142\">",
"      Plana M, Garcia F, Darwich L, et al. The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. Immunology 2011; 133:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/143\">",
"      Alpdogan O, Muriglan SJ, Kappel BJ, et al. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 2003; 75:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/144\">",
"      Chu YW, Schmitz S, Choudhury B, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008; 112:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/145\">",
"      Taguchi T, Takenouchi H, Matsui J, et al. Involvement of insulin-like growth factor-I and insulin-like growth factor binding proteins in pro-B-cell development. Exp Hematol 2006; 34:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/146\">",
"      Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/147\">",
"      Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/148\">",
"      Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol 2005; 26:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/149\">",
"      Chen J, Wang J, Li J, et al. Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession. Mol Ther 2008; 16:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/150\">",
"      Chen T, Burke KA, Zhan Y, et al. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007; 35:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/151\">",
"      Li L, Hsu HC, Stockard CR, et al. IL-12 inhibits thymic involution by enhancing IL-7- and IL-2-induced thymocyte proliferation. J Immunol 2004; 172:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/152\">",
"      Eisenring M, vom Berg J, Kristiansen G, et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/153\">",
"      Satoh-Takayama N, Lesjean-Pottier S, Vieira P, et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010; 207:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/154\">",
"      Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007; 25:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/155\">",
"      Chen X, Esplin BL, Garrett KP, et al. Retinoids accelerate B lineage lymphoid differentiation. J Immunol 2008; 180:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/156\">",
"      Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res 2001; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/157\">",
"      Zoller AL, Kersh GJ. Estrogen induces thymic atrophy by eliminating early thymic progenitors and inhibiting proliferation of beta-selected thymocytes. J Immunol 2006; 176:7371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/158\">",
"      Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/159\">",
"      Kincade PW, Medina KL, Payne KJ, et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000; 175:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/160\">",
"      Viselli SM, Reese KR, Fan J, et al. Androgens alter B cell development in normal male mice. Cell Immunol 1997; 182:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/161\">",
"      Igarashi H, Kouro T, Yokota T, et al. Age and stage dependency of estrogen receptor expression by lymphocyte precursors. Proc Natl Acad Sci U S A 2001; 98:15131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/162\">",
"      Medina KL, Garrett KP, Thompson LF, et al. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001; 2:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/163\">",
"      Heng TS, Goldberg GL, Gray DH, et al. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol 2005; 175:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/164\">",
"      Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/165\">",
"      Williams KM, Lucas PJ, Bare CV, et al. CCL25 increases thymopoiesis after androgen withdrawal. Blood 2008; 112:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/166\">",
"      Greenstein BD, Fitzpatrick FT, Kendall MD, Wheeler MJ. Regeneration of the thymus in old male rats treated with a stable analogue of LHRH. J Endocrinol 1987; 112:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/167\">",
"      Olsen NJ, Watson MB, Henderson GS, Kovacs WJ. Androgen deprivation induces phenotypic and functional changes in the thymus of adult male mice. Endocrinology 1991; 129:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/168\">",
"      Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004; 173:6098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/169\">",
"      Goldberg GL, King CG, Nejat RA, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol 2009; 182:5846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/170\">",
"      Erben RG, Eberle J, Stangassinger M. B lymphopoiesis is upregulated after orchiectomy and is correlated with estradiol but not testosterone serum levels in aged male rats. Horm Metab Res 2001; 33:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/171\">",
"      Ellis TM, Moser MT, Le PT, et al. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 2001; 13:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/172\">",
"      Erben RG, Raith S, Eberle J, Stangassinger M. Ovariectomy augments B lymphopoiesis and generation of monocyte-macrophage precursors in rat bone marrow. Am J Physiol 1998; 274:E476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/173\">",
"      Masuzawa T, Miyaura C, Onoe Y, et al. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 1994; 94:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/174\">",
"      Dudakov JA, Goldberg GL, Reiseger JJ, et al. Withdrawal of sex steroids reverses age- and chemotherapy-related defects in bone marrow lymphopoiesis. J Immunol 2009; 182:6247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/175\">",
"      Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 2005; 80:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/176\">",
"      Schmitt TM, Z&uacute;&ntilde;iga-Pfl&uuml;cker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002; 17:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/177\">",
"      Awong G, Herer E, Surh CD, et al. Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells. Blood 2009; 114:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/178\">",
"      Reimann C, Dal Cortivo L, Hacein-Bey-Abina S, et al. Advances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation. Immunotherapy 2010; 2:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/179\">",
"      Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008; 26:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/180\">",
"      Holland AM, Zakrzewski JL, Goldberg GL, et al. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. Semin Immunopathol 2008; 30:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/181\">",
"      Vago L, Oliveira G, Bondanza A, et al. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood 2012; 120:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/182\">",
"      Gill J, Malin M, Holl&auml;nder GA, Boyd R. Generation of a complete thymic microenvironment by MTS24(+) thymic epithelial cells. Nat Immunol 2002; 3:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/183\">",
"      Bennett AR, Farley A, Blair NF, et al. Identification and characterization of thymic epithelial progenitor cells. Immunity 2002; 16:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/184\">",
"      Depreter MG, Blair NF, Gaskell TL, et al. Identification of Plet-1 as a specific marker of early thymic epithelial progenitor cells. Proc Natl Acad Sci U S A 2008; 105:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/185\">",
"      Rossi SW, Chidgey AP, Parnell SM, et al. Redefining epithelial progenitor potential in the developing thymus. Eur J Immunol 2007; 37:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/186\">",
"      Jenkinson WE, Bacon A, White AJ, et al. An epithelial progenitor pool regulates thymus growth. J Immunol 2008; 181:6101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/187\">",
"      Bleul CC, Corbeaux T, Reuter A, et al. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 2006; 441:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/188\">",
"      Bonfanti P, Claudinot S, Amici AW, et al. Microenvironmental reprogramming of thymic epithelial cells to skin multipotent stem cells. Nature 2010; 466:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/189\">",
"      Chidgey AP, Seach N, Dudakov J, et al. Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches. Semin Immunopathol 2008; 30:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/190\">",
"      Seach N, Layton D, Lim J, et al. Thymic generation and regeneration: a new paradigm for establishing clinical tolerance of stem cell-based therapies. Curr Opin Biotechnol 2007; 18:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/191\">",
"      Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/192\">",
"      Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 2010; 16:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/193\">",
"      Ott HC, Clippinger B, Conrad C, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010; 16:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/194\">",
"      Petersen TH, Calle EA, Zhao L, et al. Tissue-engineered lungs for in vivo implantation. Science 2010; 329:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/33/37402/abstract/195\">",
"      Seach N, Mattesich M, Abberton K, et al. Vascularized tissue engineering mouse chamber model supports thymopoiesis of ectopic thymus tissue grafts. Tissue Eng Part C Methods 2010; 16:543.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16355 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-0039180376-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37402=[""].join("\n");
var outline_f36_33_37402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6875688\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6875497\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6875504\">",
"      OVERVIEW OF IMMUNE RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875511\">",
"      Innate immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875518\">",
"      Adaptive immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6875527\">",
"      - Recovery of the adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6875534\">",
"      - Recovery of the humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94783236\">",
"      MEASUREMENT OF RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6875541\">",
"      EFFECT OF TRANSPLANT CHARACTERISTICS ON IMMUNE RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6268181\">",
"      Donor and recipient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875587\">",
"      Source of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6268213\">",
"      Graft manipulation and cell dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875594\">",
"      Conditioning and immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21151647\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6875601\">",
"      THERAPEUTIC STRATEGIES TO IMPROVE IMMUNE RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6155646\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875610\">",
"      Cytokines and hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875652\">",
"      Sex steroid ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6875659\">",
"      Cellular therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6875667\">",
"      - Precursor lymphoid cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6875674\">",
"      - Artificial organs and bioreactors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6875688\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39145?source=related_link\">",
"      Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_33_37403="Assessing O2 need inflight";
var content_f36_33_37403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determination of need for in-flight supplemental oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        SpO",
"        <sub>",
"         2",
"        </sub>",
"        at rest breathing ambient air at sea level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Further evaluation needed",
"       </td>",
"       <td class=\"subtitle1\">",
"        Supplemental oxygen needed in-flight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;95 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        92 to 95 percent without risk factors*",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        92 to 95 percent with risk factors*",
"       </td>",
"       <td>",
"        Yes&bull;",
"       </td>",
"       <td>",
"        Depends on further evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;92 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SpO",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen saturation measured by pulse oximetry.",
"     <br>",
"      * Risk factors include: Hypercapnia, forced expiratory volume in one second (FEV1) &lt;50 percent of predicted, lung cancer, restrictive respiratory disease due to interstitial lung disease, chest wall abnormality, or respiratory muscle weakness, cerebrovascular or cardiac disease, exacerbation of chronic lung disease requiring hospitalization within the prior six weeks, pulmonary hypertension, previous dyspnea or chest pain during air travel, or inability to walk further than 50 m without distress.",
"      <br>",
"       &bull; Further evaluation includes use of a regression equation or hypoxia altitude simulation testing for prediction of in-flight arterial partial pressure of oxygen (PaO",
"       <sub>",
"        2",
"       </sub>",
"       ). See text for details.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37403=[""].join("\n");
var outline_f36_33_37403=null;
var title_f36_33_37404="Common cold treatments in pregnancy 3";
var content_f36_33_37404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Diphenhydramine",
"        </p>",
"        <p>",
"         Chlorpheniramine",
"        </p>",
"        <p>",
"         Fexofenadine",
"        </p>",
"        <p>",
"         Loratidine",
"        </p>",
"        <p>",
"         Clemastine",
"        </p>",
"        Brompheniramine",
"       </td>",
"       <td>",
"        Clemastine and brompheniramine (and loratadine in conjunction with pseuedoephedrine) decrease sneezing and nasal discharge but have no effect on sore throat, cough, headache and malaise. No antihistamine effects total symptom score or duration for the common cold.",
"       </td>",
"       <td>",
"        <p>",
"         FDA pregnancy classification B and C.",
"        </p>",
"        <p>",
"         Chlorpheniramine and diphenhydramine have mostly reassuring pregnancy data and should be considered the preferred antihistamines in pregnancy.",
"        </p>",
"        <p>",
"         Most of the older antihistamines are not considered to increase the incidence of congenital malformations in humans. Although some antihistamines have been associated with oral clefts in retrospective studies others have found no significant increase in the incidence of major or minor malformations and one study even found that significantly fewer infants with malformations were exposed to antihistamines while in utero than were controls.",
"        </p>",
"        <p>",
"         There are limited human pregnancy data on the newer antihistamines fexofenadine, cetirizine, and loratadine. Therefore, they should not be used as first line agents in pregnancy.",
"        </p>",
"        Use of antihistamine with women in pre-term labor was associated in one study with an increased risk of retrolental fibroplasias and should be avoided in this setting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Cough medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Codeine",
"        </p>",
"        <p>",
"         Dextromethorphan",
"        </p>",
"        <p>",
"         Guaifenisin",
"        </p>",
"        <p>",
"         Benzonatate",
"        </p>",
"        Hydrocodone",
"       </td>",
"       <td>",
"        Uniformly ineffective in the setting of cough from common cold.",
"       </td>",
"       <td>",
"        <p>",
"         All FDA pregnancy classification C.",
"        </p>",
"        <p>",
"         Animal data for codeine, dextromethorphan and hydrocodone conflicting.",
"        </p>",
"        <p>",
"         Human data for all these agents are poor. Guaifenisin was associated with inguinal hernias in one study only. A large case-control study observed an association between first trimester use of opioids and various congenital anomalies.",
"        </p>",
"        <p>",
"         Neonatal withdrawal has been reported in babies born both to addicted and non-addicted women who took codeine in the days prior to delivery. Codeine ingestion near the time of labor can produce respiratory depression in the newborn.",
"        </p>",
"        The lack of efficacy of these agents suggests their use is not justifiable in pregnancy for the common cold especially given questions about the safety of some of these agents in pregnancy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37404=[""].join("\n");
var outline_f36_33_37404=null;
var title_f36_33_37405="Survival after liver TPL in PBC";
var content_f36_33_37405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Improved survival with liver transplantation in primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival probabilities in 161 patients with primary biliary cirrhosis treated with liver transplantation compared to the simulated survival in a \"control\" group calculated from the Mayo model. After six months, survival with transplantation exceeded that predicted with medical therapy alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Markus, BH, Dickson, ER, Grambsch, PM, et al, N Engl J Med 1989; 320:1709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37405=[""].join("\n");
var outline_f36_33_37405=null;
var title_f36_33_37406="Pathogenic mechanisms PD";
var content_f36_33_37406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possible pathogenic mechanisms in Parkinson disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 480px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37406=[""].join("\n");
var outline_f36_33_37406=null;
var title_f36_33_37407="Accessory auricle";
var content_f36_33_37407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Accessory auricular appendage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAQMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD18gAEcZH1zTXUsoBGM9OP8+tWomWKJiGYtkEjHA/Co5ZS0h8xRkD06frXgWPaUnchXhCM556n61KsrpCFTIyeoppKbDj72fT/AD/n9Gg45J60D3Ed8YJIJ7cVG7DG0ngj0qCeRlXIGSPQc/5zVXzi0TgcEqe+cfQ1NzVQui5KFC8cE/55/wA9qyrhHM24AZySMYFWvOLq3mLtXgcjiqjKzTOo+YfeGTVIpaDYkYld+D83APrVHUruOOMIpJwTwOmcH/Hrmr1zIIVxJIu4ZwSM7fp715/4p1cW5cByp544zz6D2rSKuL1OM8d6u6M4t2zJJlVGO+cetbnwe8EqFj1S9UtI2Sox0GP/ANf51m+C/C1x4u1Zb68R1sIj1/vcdvxr6EsbRLSKNIY9iqMZzxn0rWc7LlRDXL7z3GpbokKhc8D5T6/4VAyEOepAHcVpbSwIToRlcDnHtUE8fzkMVx055OcisiUzzb4k6ZJPYBowBGvPGcZ9xn2r581KzMEhEinjj6egr6v8SQI+kzNNtAwCp+8Mg/WvnLU7f7RdyqTySRkjB61vRla6YqseaKaOMEXDHPA6Va0yw+13cUbDv3q9fwwpP5cAYjuD65+la+h232dlmKgu2Bg+ldLdlc5ldmzpcC2ts8A+6pAJycn8vQ1yvikLJflUJ+VQCCec11enSrFNOWwV2MRgZ5/zmuP1BvtV5NMECgnAz2qY7jlsYUsbKOR1qncW7Oy/Pxnvk/5/+tW1NEHOM49SO9QSQ7VAG0uTnpWidiG09zKtrUNKpbheh65z361dv4wCrIhCjA4H5/5961tMtBM+HO1FOeetL4ihhjhiSLG4jLkjof8AIp8wkrHHy58xs9c4pCxIAJ6dKsLbmQ7gqqmeCGzUz2rLId2SPvYxgitLoz5WUWUr94YpKc53szY4NKIn27ipwenvTJsMoAJ6DOKDwTwRT2LhVDE7T0GaAGFcg/MBjt606OMsw7L64oijDPjn3rTKjaNoyRgeo+lDHGNykI4gBvY7vZhRV5dPYqDmb/gJyP5UVF0XY++hE0Ub72QrtzyOh5/Tn2/GqJO4kknJPSrstyADhXyTzkYxWfLKFYkKPXB5rxmdkE+ouQe/QVBcSRopZmAA5yaY8oKA8gk8f5/z1qg9yGADHg9vT/HrU3OiNNkwulbIKnA7j/P0qG5dduIztyM/7w9f1NV2KlUwTz26c1SvbrD7ccjHOM9qEa8pcEgY4lkAXPDEd/T6U5JwowQqkevTPb9M8is37R5SgyudxAB4z2HTBqvc3gOTH8oPtnP4VSTYpIbr2oIq7+BgYOSOTXmsGm33jHW0jgVxahjvkCnA9eccdvzrcvbS98TawbCwJCoSJZS2FHr/AD6V7D4Z0O20PTorS3UttA+YgZPTP16Hmtk7bETkqa13F8OaLa6Pp0VrbLsEaA5HGeucnmtl1UnHAyMZx/KnkYccADPsD1//AFU9lOMLwOgx2pHG5tu5TlhQxjZkDoSeDj/Iqu6bUOwYJHHoKvyLn548Fsbcjt3zVYrkOm0YA+6D2OaRcWcj4py2mSLGncdB0HXOeteLXtkqTSl8JsJ+boGH0r3bXLVXtHJKiIZJLDoBXj3iG3aZ3EP3APmfJxjtxRB2kdkUpUzi7q1SWSPy1J5/E1qLbfZrYbgOeAD27c/nVlbAxAzygIinAU4JaqtzK8zbASQcYA4rp5rnI4NblN23owOSDkGsu+iaNYYofvOTk46f55rda3MTJET85yP8/rTf7OaadDt+XH3j/DVKViHHocnJbSoBlSc5IAqey0ea43OAVYcgEHJ/CuuXSdkSYVTI3Zev1rY+wiMxeVGo2DLKDnJp+0JVI4hLSO0iDSZVw3171h6ikkkp3Dbk5x7V6PrFgwihMkaiST5t2ByDWbNpcb3GH2FkUcgZyaamKVM4a0sRLKFRdznk5pdTsmhkITr/ADrt9O0UQSSOD5i7sL+OOPao9T0gSySZEZm7BR2/Kq50TyPc88GngRKQMknJHQg1FPap93aFAOWwMZrvDofkRIkyMXZQ3A55rE1CxNsdj4I+8ARTU7icbbnKXECtISuV6dutNmA8lUAAAYDce3Wtm7hiSFtwIZnHORnFZkkShwFVlVc4OcHH1rVMhrsVYQEkXnJbpkcVekJjmcL+7I4AHf8Az/WobZAkmSckYAyOn+TWguyW6MkgxtU5z35odxJWLsV2ixqMouB0FFYUk4DtulYnPXGaKqyFzH3xczFi46rnO3rz0qi7lhwq9Keeh3nAHHHP51Tu325Cuck8k5rw2z04RWxG8hCtuBVeuGPTH/6jWRdzxK4CupZuAKvzDdFufLZJBHase5JLncOR2A7deam1zphYmilXG3gYHGf8+1Urh+SWy396oLqTZGQnBA5Oev8An/JqpBM0qkPtKhTlieKpR7l+aJnyGww79OarIl9q9wLaxyoPDSdNo+tWbGyl1a6kt7cYVeWcnO2vQvD2ixabaIqLuydxLfxHpnA9vX2rW5zzmqa13K/hPw9b6XYhI1Bc/ekbBLHIPOP88+9dA6EsSMnBxgZ/me1PGBjOWK8dc4+v6UjMsbEnOSST/n9KNjhlJzd2PACntk0jtsGTgfWo1lDSAIPl9c8U8gNnrtPfPBpXFa24u7Byfpg9qoEli2FyT3P6H6VdZBz8vfrjOKhKFTx8uewH1oKhZHO61ZSXlsyk7wByi9O39e9cFq+mzb2EcBHsF4BHOf8APpXrUgcFFYZjA456Y+n9ap3NkkxPmrnktkYpNHXSrcqszwq80m6mfyyzPIxIAIIwO3FXrbRbfSoGaSLzrxgSu7+E9uteo/2bbWjP5ca7m74yf5Vkr4a89/NkYbiRwBxT5mbc8Zas85stGkkAeRAHYgDkHFdNa6LFHDzHnYMYPc+ldudFUsNqbdrA56ZPTFW7fTA0m1QGwPvAk03Jsyc4JaHBXGjDyY5mj2f3Rjkc+npzWZJpbNHLuySTgbe4/wA9q9U1fTTIixRKVXkcn6VGNFi8q3DDO3ggjr9KTbWw41ItXZ5l4gtY5Xt0TKqkQXA7D0z+FchPbXccrBoppFxgMiEgKO3SvoF9EhDRjAI7k+1XhpVrGqqyoOOuKcakl0Mpum0fOlrDqLII4bC6OX4cRHHOPbjtVqy0jVEuJZZdNnIbOGG049/0r32K0sre4fgAdRk9Tj/PSrixWedyquc+ven7WXkZvkXRngsOnyeVcS3UU0UqD5V8vJbn19Px71y17pa3TM11EkUfG5FbJDf5NfUMtjaTlQVXIyOD/n0rA1vwbZXynEeM8DBOQO9ONVroHuS0vY+ZLzRreECYhgpGVAPIHSuZuLRPMkVFYJn/AD/M17J458IXenpI7O01qOcdcD3Nea6haxr86OXJwAirjHHf19K7Kc1JXRhUg4PU5URCOQjOJOMY7065kZpPstumfmz8oySfWrc9s4uHPDtjA68GoYrUrBJIXQS4xuHRfX68VsjJ6mDLC3mNsRyv0zRVpo1yfkLe+P8A61FWTyn3ZIQgOTn1yO1Z7OJGxu6+o4q5LCo+8cnoecflWbKgUgocgNkHP6V4Z60UDIuQgIUHnGOvbPt+NUblVjVnXBPXOCfoasFXwGYnHbnGR7VlarcER46AckH1oujWKfcyb+ZQxGDz0x0P41Y0LS7nWJsQ7lhX5XbdyRUNhZSatqEUSoShPzNweOfTt9K9W0LTLfTrVIYI9gxye7e57/8A66tK7JrVVSVupBoulRWFusSIAU6kY6/hWmwxk8Z+nOKmWJY0EaLgKMAAcAComYByARx1FaWPMcnJ3GlflwP09fWs6T55GJXg569R0/wrQJCt7559frVK4Qpu28joBjp6fyqGaQGRuVlAyFGcHHFXlO8cAjngk8HjqMGs6SMqRg/N1JqaGQxMoKrx36VKZco32LzHapIA4/CoZNwDNySD2A6URTB8gHH9KJmOCMDIGcn8cfyqzNJpkUiMGyT83Yr29qhOWztYf72QcD9asFN6goue5yBz9OOaglysqANtGenp/nmkaIqmDIDEHAOSc9fwpREAoYYX1wf8+lWHgVlZ0JY9MBcY9vyzQ8TEYILDkdOv+Heh6FKVxtuqzZB6emOtaNugjXGSe+aqW1tk7lOB7ZHPrT7wzxxB1IwoGfUmhO2pEvedkXSikEn61BPKkfUjIOMVn6PqJupSjjlcruB/z6VV8WTSLZyIpbDYBx/9fihz0ugjSfPyMpa3catMyvbwGOzPIlUbm/Lt/n2rX0uKxmgD+ZLKP4jIxJz+PA/KtDQ7Aw6XHGsy/Ki/6wlgeBnOTx7c0j6dZu++WLyZWxuKcZx06VXI1qVKtF+6tLdjRsY7VY1HlIB2G0Yx9Pyq9vhIK/IR0PArnzp0sSgw3DMMZHAPsKg23iA5bJHTitPa8qs0c7pKTupG1NHbhgfLj4OcBfb2pJ4IZkLwnY+ORng/hmsdbt1YCRgD6E/1qcPvwAwDdStR7RPSxXs2upV1eyivLOQOgcMuOeBXzd4y8PLpGsytJgQTsTzgAEdhj0zX0xJKw3oyjJyQM84rw/4yr5cUEkXDLOCpPP0/X+ZopScZrzNlHmptPpqeR3Vosky/ZxtJc5B71l6ofKQpy+Tt4HFbccn2e9u2cs7rycnv+FZUyll87ywmT2PX35r0DjK8OjF4w0snznk4NFaIW7YAiVcH1H/1qKd2K59Z3MjHICkZPY9PzrNZiNuSd2fyrSuUAmIYoVBxgc/59KozIN3GBnp6f5xXjnrRtYp3V0IztO7rlfb3rCnSfUbtLaNHZmbkgE1qagUO4gjeOK3/AAHpyN5tzImZS2AcA/5/+tTSuzSU1ShzGr4U0RdMtVGAZWHznHeulWM7fmGBjNPiiygKHpx2qyVIBKn3GBXXGnZHj1KrnK7KssYClQBn8KqSxfMDjnnuen+cVoTqyplF+bjgVC6ZfBByMZ9qHAmMjOKnO0nnPp/ntURQswDgYxg8cHr+NWp0LkkMQRjuBx/nNVFGHC5O3H0/Ss5I2iyvIvlhsnJ6gYxVdVLNnOQBjkDn3/z6VYkXkqwzg5+7/KocEjBHI5PNYvc6E9CRH2qPmIxzjPGakkdWUrwAQMDpVVjgYU/JinxMRJHtIXjG4849aLia6lvBjjCq7YbpjnqPaliiZtplHOfuk5HI/WmyOUXJQ56ZJyR9P0/+vVmM7hkEc4PT2FUjJtpCsu4YOOevFLtIHWlGM85qVgDwDk9veqsQ3YiRVX7xAz3xWP4k1aztLFt8ibmHAyM57YH5Vl+P5NYS1gi0d1hErbJJWz8gP8Qx6c/nRoWiWlqkU2o3LX10F5edg3Jxnj/PFJu6sjenBK05Engq1mSxa4mVh5zl1D/3TyD261r61Y/bbQxggMB2PetQXsHkqhCptBIOO3GapS3trHIA7hARjDZA7d6pwja1xe0nKpz2KukXjiJIbn5ZogFxjj2/pXRQOJ7ZkGckdcdazBHHIvmI6EH071Zt2VY+W7HINVBtbkVbS1RnvdfZLlYwNqseFB756Yq+0iuucfMe4rG8RIsoEkbASKT3xnuf5VW0zUZZ1CsoGDg7Tms3Ozsaey5oqSG64WgkZhjGM4xiptLnZ4FYlcKOOayvEdzvHc7hwO9WdEffbIrkmNRuPGd2P/r1mnqdDj+7VzTu7kRQvK55/LvXzr8U9ej1LWItOtSWWGXdJ8w6gDjH4/oa9N+Kfi+DRNNkijZRcNlEQ8846kHrXhGiWc99IL65bfJMxkH+1t/yf/r100Ia87MJy5Y8q3Y+7tFk1WVkLbJJcBCvLGpr3T4YNk1yFOwBFTHfnJPv0rVlijW6MkzgLECSyn+L0+grntRmubgb7l0SPfiPAwT7D8PzrqWpytWLtva2jQq0zXCOc5AA9eKKije2CKN0hwAMtLg/lRTdwSXY+kb1FEhKuG54x/SqEs3l8SEnnA+mfrRPd5Y4B47ZrNumQqXfCqCWPbk/1ryea7PZjDTUW3tvtt4qKxJLd/54/DPavVtHsUggVYwVAHULjvz9K4nwNp/mXZuXTITIQn9f6V6PCBGpIPAGTwa6aEbu7PPx1TXkXQlRcBTgZ2gE4wacCGUEEEEZBB60KRtHbjPTpUbv84KMOAQR711tpI83dj5VVkKuMqwwRjOaqXCo5wx3bTkggHP51IZSPl+YkYH+eaqsyKQD/CvLn09z+tZykmaRiQXTN8oCruPUHpjuKrYOcEHB6keuamkYNuQPzyOvI/L8aib7gIVcDnrwDXPJm8StKnzMwBBYcZGcY+v+e1QzuZB6k4z9asXErxkBmG5lIwBxn/PrVF+AQT8hOc54xWbN4CHOcqpIPv3pxbJ9D6UyPOzAHfHFPxg9SSM4xUFly3EUmFJJIzwe49KtgdRjHbPrVBISuMuo3DAHOcf5NW0l+QFgT2P+f8/SrRjNdiRcY4OQOOuai3t9rCL90Lk57095NozgnPQY5qCJ83OWI5HHNFyUixKElGZAMAd+KgjtYMAoPlPYcVa69KVUZT8owAAcDt6U7CUmlZFaeIlcrgY9BXMatp01xMCZGwOhx7V2OxyCcE+pqKSFBy6gH8qTjc1p1uQ4FDcaXMdruqvwShIH/wCvium06a4uIVczwgEZ5HNWL20ikQoVHPfFYsenGO5zFkA8YUkUkrOx0SlGor7M3X0mKZi1zIzkHkZwP89Kk2WtrFtTA44Hc1kRQt91pHwwyf3hJ/nzTZpY7UtllKjruP3fxPWnp0Rlyt6Nkd7Ym8mLE7UHoMfzrF8Ta9b6BYSSu6lV4AJAJ/D8D7etZHif4j6Xp7SRJM0kiDaETJyT6evWvItSm1rxzf7kjkNrkBY1ztUe+T79f8KuFK+rNXNpW3M3zL7xv4jLOSY3cYXPA5/z1/8A19pFaw6eywFh54UL8w5Dd+M+vFbGi6TF4bs4BCgE6j964B6kHOCfbj/CqWqGKW3VnbLgM8kmckjt9OOK6OZPRbGEoNavc5+5ETTLCQRJI/7wjnH4CsLWCkQZUX95HgNkfxfnWq07QRlyOQRjnO7JOPwrKvWM8cxyJGeRmc+h9K0juYT2KEd1FtGdv4nn+dFVxBgDDKB6E8iitbmdj6QvGSNjJkBcc9KoxTG5uFhCoEkAxzknP0qpqdyCPLjZgc8444wK3fh3pqXGoSXEqsRCAV9+f/rV46V2e9OSpxbZ6N4ashY2aIobavcnk1s7yjEEE5Gc54/z/n1qrG+1cADp64pZJBs7k57V1p8p4Em5u7JfMwFHUY4PHamShSwZsBxwD3GagL7u9NJ7Yx9PpQ5jSFLFmJHuOcjPPv8A/qqNpmLBGyAc9O/4/Smu3JJbC/XFRtw4L7hgggg8c8Y469alspIcVABCYx6etVrmfa6qAcg88cCnXMmwMQ+HAxk9s9+lZ/mFSclW7EHvjjt+FZtmsI3HSby4Lk9OD0P+eaikO1vmXIXIHHU08yeY4PA+nGOtSvbsirubnGVA59OKk2ukVwG3AgY44wPxqeHeShUbucY/OpIIBLGGBK4fnjn6Vahi8piNynJyABjj/OKEiZTQeXlF2qm/GQSuMUqr5YJIAA544FSA9M9evHNNePcO457GqMrlF2cuQvI5HAyODgjP160yVcqh53HgEc/pVie3YqDu3Ed+OBmmGIKpbeOuAc/oKVjVNFaPUJrUFZYnlUZIKdau/wBu2n8cyoewf5T+tQjDDZlQx7HgHjp7Uk9rBMhjlSN4yMbWXIPbv/n+dNeQNRb1QXnirS7fc093BGMc5cYP61zGqfE3RLUBY7jzm54j+f8AlnFadzoGmyAI9rbru7bQAc9e1RHw/p8YDfZYt3TcVGMe+frRr1NIwpLoclL8TzI7fZtIvpU4w2AevQ4HTqKB42vjkyaNdhc4AUAknsK6mO1tIRsjRFAORtXAP4U2QRIoyqYA6HFPQ0vHojg9R8Za9tUWOkrEzHAMpLfw89Me/Nc3LZ+K9elDX1y6xtkFMhRg88qB0Feq3TKhDCMK3UNkcEZ/z2qg1zErKfMCsQclc/hxVKaWw+S/Q4vTvhvZ284l1CVriQuAUHy849M/TvXWSJbWAWGziSNVH3Rxjj2qrf6sWwYlIJOS54yev481mQyOzCUM3kjJLSHGTS5m2V7Oy1E12/Qq0cjAEqG3YwAM9K5Se5E9jIUDKhHJI7HPTGfSrepxrNNyyhnck7CfmxyfrzWZqLQW9s8SDc5IHBGV/wAitoaHNU3sR6ltmtbeOUiSSWQSEgdv7uOf8/pFfWi28MsZzu5ZeMg9vb2qxZRCW3Mrl84Urhs8gnH61W1u7/09IAzZjXDMxwB7/wCfStFq7IwlornGXCGKVkO7I64FFdS9pJK7OFIyTn5j170Vrzozsz0e4RhIFcZlPGOSc16v4S046fYJGQVkIDNkDpj8e9eceGQup6/vyGSJiX4z07Yr1weTGyAMqnqMEV5sNNWehjZt+4i152FJPGODk9vWhpAW285AyDg4qm9xHt+fJ69M49eD+HFJ9ri4OGzjPTp/nH6iq5jhUGWQSOnA9B0pjnejBzhff0qnJfHrHtIPrUL3DMpJdlYnoCR/n/61LmLVNmk8gjUMxCnpye9QzNIHJBCqPfr9f8P1qpHclc5BJ9dxP9aVZQuWUEDbtHzZOPSlcag0TXMTGQYZjyMAJ/M1Xly3DKDIAc4GAMHOR9etTIJWkLMzEHnA3AdO2KmWIcK4HJPIyPXj/Pb6UwvbQr20Sk+YoDOSQCf54x9f8mraKqdMMclsgf57UoQKoQZC4xwBz9fy/WnoylsqTkjiglyuLRjByT14ApMHJOe/FKMlRxgntnpVJEi89wfrjrQM+lKMt14+tNbgYJzzRYBpXjjj6Go5tmxwQvTjP6VKRkfUVGArFXDZbOOD/n/P41JSK4jC/Oiq+OmKWb5VGFGBx0P1/GppP3cWOTx3JJzVNy0js8YPbgevr/n2qdjRa6jZGbBwcd+BWXqLXIXELgNnA3jOB15AIrQZyGJbr35xUM7AKwbkE9qLmsdGcyXuzKWZl46HtgY64pszsSS0qBhkcA9fp61o3ijkKNzEjqOM/wBa5rWri6jYmDaQFySo5/8Ar0l2OpPmC8ljk+ZZm3ZwW2gCsO4kiR2WMlvm3Zbnrz1rkdS8TSiaQTIEAPXJFZcuuJcNgSM57bM9f8+tbqk2iHWjE7CfUItzbpAxPpz/ACqob/Mas74znagbp65/+t61yc2oLH/rWVWx/ERnOOnFRjVF2v8AOdoySxHWtI0rGM69zpnvIUPLbtn8R6ZJ5/8A11Rk3Xs7+VtbcQW+XHy4rEtr9bt2ROAOdtbsZSzso5ElwXBLuFOOOevFXaxg5XLdvci1hDOql0wobd8pbnA6YIGK5yVy92XumklbcQ+Sc59f1/StXa1xHFKw/wBHBwmSCMdyR6d89fzzTLg29s7yR43kguS/6enX36du1XBWMpu4Q/aBGAgkCgkAHb0zRWO188jF2+15bn5EBH596K39mZc57p4JsDpdnh1fzSuWIxlunGPzrrkuHZfu+348f41FBZxp82MA4wCMcY9P8asxxqi4ABz/AJ7V5LPRlNS1EjMm0bmO7GcYznntTw0h++MYNJwMAg5B9f61KqM7fKu4seOO9FiHIhjUGMDHHXGQalH3TjqBgVYFq5jG5Cp9WIAxjv3qWGFU8yQHftHAHAIz7/SlYTmisiliQuBxkkkAVejt9iqrOMZBIxwT07/T86l8uJVCsihenzY7VIpzkAYxxTSMpTuJGpSMB23EDljQ6Zxvw44O3HGRzn86cSNjMQSoGSAMkd+nXPtSIu4YIwP72B8wPpVpGdxYwQOWYkk/ex60iluAFIbOcEg9/rUmwHkhgTg9aevJYbTnPX0p2Fcjwe9CpyOQMdu2KnOCOgUn8RTCNqgjjHTigVxpXBppBp7HDquCc9/pSPnP/wBagaZHgcnJpDgcnHHelPXvTZFbHyNgnvjNSykVHlQxDJTPG4hcc+o5PtVcTFQwTK7jnIPNT3ARExkNLnrjFUyc4OAM/pWbOiK0B855PzH35+tVJ3AZstnHFSSheSV3D0zzkf5zVG8fY20hc9SR6fnUtm8I6kE7k8CTO08Ed657Xo5pIisEi7jngjGBWtNKUAUg8jseOfes28uF28lg444fnB7Uk9TpjGx454ttrt3lF1b5lAxvGcN9M1wMwuItxRQcE5BHT617l4q0u5nUy2Sg7Rkpjrj0A715Rr1vMk4aaN42I+YFSMe/5fyr0aE7qx5+Jp2fMcs+oyK22QLH14AzxUkeotKqhpHKg4A54/Cs+9AEyllIBBOck5qJZgBznPbjgV1pJo4m7Ox1em6kYsspyV+6v8P4+v0rZj1We9hSOSRCwB3Lzgr3GOmOnQV5/A7vJlCRjjgY4rd0ud4cO0oIQBVXbncQOnT9KXs76hzHVyXRjCvJJk/eyxzz649f8MVm31617lIXdbcDc5LkhicDI79/19qzdQ1J70rGVUQrklQPvc9c9QOP1qeztzcDPPljABAzjjgDH9fStIwsJsuRLPLGriWbkdiaKifUGjcpBHEYhwpfriitdSD7BA3E4p+x2bCgjPXvn/HtUQYdO9WYm4BJUop6HHP+NeGduqBbdy4YDaRk4JyeD/8Aq/z0fHuFxuACknaQMD9OcVJng7GXH3gMZwcnp/n+lOZm24bO48Hpk/lRYm5JFlLcKXAbsScA8cYz+FEpO3O5uehHT9O1NZDtyWAOCM5/SkVACoRs5xz6d/607ElmPlWGSWPPPH/6hTlDeWNuxX6Y6iqiAfeLKjDBGRjipw4VWy+R1GTjGaaQmTDYqAnauPUAYFKcCXIVtzAAtzjH1/P/ACajLEAD7q46D8KdGd2erA89xxTSJZMWVSoJGT0HrT8ZHJ29xxUQIzjA6dMfrQNxBCr9Pm6H2/X8qLCFIHJO7gYznikDsE5HzYyRnI/OnFhkgAY6jnk0uw4yAce1IaIzy/3Tnmm84wTz3xxT5mZI2YKzEDO1ep9u1NO4DjApIaGScrsUsrFfvAdP0xn60gOe4JHXFPJzTR06VLKRl3CsrBZHLuoGS2Oenp/KoJMbMhsf1q7cCYxgSEYBO44/KqUg5AxwM98VmzpgVLh9sR+ZcEYwe/esy6dS2SwUnjngn3qxfACT5mO3qFHrWdc4HQkc4HGc/h0rNs7IIrXU4XOXwGIxuOPyrK1FidxVySf4c9eeMVLfXphwGUsG7561i3V+C5kaRVIXDe3rRFG60HC4kVGQk4PGT2ri/FdrPdySmPY6hcbQPmz3rpLi+hRC5dXHchs4rDurwSRgvkBgeeBu6c4ropXTuY1opxseP6pZEqdpwyZ+U9c1iV2viJU+2TFcbe4APf29f8a4yUBHYDoDx9K9Sm7o8SorMlt2YOFAyDzxV5po2dtrDaoA9h+PrWSsuOSAaswvJMQFVQpPTHFdCMFJbGvb7ZZBGoYR/wAWc5NdJDI1tbKN8kaEEuy8j1P44FYOnlIwSzqCBuw3O7noO3TJ/P6Ft/qkuoXkGn2ke07hGp3Dr0GT2568Dj8MNK7KlJJHR211p/kIZNTCORkqxYkfXAIz+NFbtt4EszBH5zymTHzESYyfoBRXV9XkYe1R9F2s+VA8zOeAMEHNXY2wck9+MDNcNpusrMSqPyOMeg9efeunsrsOow4IY9ycn/CvmdUe3KN9UdDE7OF+XHpjGTUytuKsDg98f596y4vmIww681oxnKnLLnODx1PX+tUrM55K2xIHDFl3HDcHHXp2p6xjIUA8HqwHPp2qHlQCG75+7j/PerEcnJO4AE8k9a35Lq6MHKz1GsVLZJwAOgPGfyqVTu3cfT/IqB24BToO5A4p8aZY8Ekf3TjHX/61DghRm29wUhWA3AgcDgD14NWMkhuGwDyCcY9eahZlUuC2HA3ZyOoHT+dOUyuOFY/j1+o/ClyD5hwy0e4LjuCeOfbH/wBapiFKssjnHQY4IyP51Wik8sBS23HzEA44x059KmypA2AHHzELj3/woaAlBwxCjg+lHfsKTbtQjaAoPT0PWlX73r35rHcYhBHWmMeDmpDnOMdPSmOMjikCIsjGcdfWkPHWl+tIeeoHWoZoZd0T5gDAhgMHPOPxqjJIAm7DdOhrQumckBsgdeVwSazL9GaM4BPGTgn+gqGddPzM66k3yhvQe5qtPhQQ+Mk459afNuVGC5DY78c1WuDuRgQME7c7ulZHYkZF3axyysxXG7pj+H/GuQ1PQ7dvNeN2VyrYCuMMefr+VdxdQ7ieVxuz64/GsHUdKdhjbvDEn5c/5x+NaRlY0tc8p1aW80iUpvE8ak9Fwcdjz15rPufEHmf8szwuSCeR3/Gu91XQo5FLrvd14AwPXv61w2t+H5N7varHjqQeAPofSu6nKMjzq0akOpzuoXPnvuySDycVzt2jCZs45OeO9at7ZzrJsmWSMgZwFJHXjPrWPJuVyGG1s8gjGPwrsgup59Vq1mIkWThmx7AZJ+laVqnyRqMKD3z+HNU7ePgs2AoBO48D/wCv9KsCeeRxHYxyMc9EXPPsK6UjmTS1H31w0QEMBPmOfmHUj0H1r0v4eeGZdIspL26BivZ0A2kgGNCeh56ZCnsf653gbwS8V2L3WTGsmMoj8hW/2j/e64POMd+K9Mkh5IcK4xhlAwU9F69OSfwruoUOX35GE58zsNic7ABE4xx0AzjvjNFRXAgMpMrOHIBIPbjpRXRYm5wnhHxm3mpDeERuTgnnB7/hz+f5V69ofiKKRU3EeYMHKnOfXP68V83vYlTlM7utdN4R1yWzvEt7mUBD9w56eg/SvDxWCsuaJ6OHxb+GR9K6dqjGP5wzADAGelatnehkwP3fGSGbJxzXnXh2+M2F3cjlSxB+o9f512FnMCUkVipJ4Jx9MYrzLWO6TUjqlnV4ULDG4E7uDz17VMPu5HQjIJ4qhZz5i5VQenqc+lXYcso3qcHnp1/KtIysc1SFycHeAOM9yScVagXdEegx/d9Kzxwx9Md/8KtRSKx2sQT05A9Pw961eqOdaMe6lH+bI9CWwe/f8vypY8BQAVJ7lPX6VE28Plc7iT3IyfofrTkwgB25UkADb3zz+n+eKi2hfUe7GRW42luO5B9/apwMqcjb/Xmod/z7gr4PoMDGeD70hf5MDcTjlvw/yaTTY7liNlIAGCOxz1+lP2gcDJyPWoYztTBbLAZbJxUqnBJwNo5/xNQ0NCZPH6U1j8uW/TipGAP3QAOuajfbkHnr0x3x+lQ0xoib8RTRjHGMeopzOpBIDYBwflI//XTcEDrn61DXUtMpagcYXavPOe4rMuiwUBUyCcemK1rqAyHeTwOD34zVBlIGMAD0FZM6abVjBuoHY5JYKeO35c1V2HJ3YYE8jFblxb78kDHHc9fwqrJaMcBFwoOM1m0dkZqxjSRbc/L8uc8dcVUnTnpkcgnsfethkxnOeD3FQSwqxJGQ3UfWlsaqRxtzb7QQxBUjv/nmsXUNNjmRtqsCey8Zr0GfTw55wR+I/wA9qzJ9Gc7mXGMZA6AD3rSM7bDklJWZ5rfaPGxIuIVPJB3559v/ANVcrqPguMsXhILHkcZH0Ne2nQ5GOCFyeeDgCopfDLEEFQSx5yc11U8U4nHUwkZHz/ceD7pXJZ/NBOAuen4Zrr/Bug29lKZ75kSXlIFYDCL3bH97jr716cvhlDGDJsXoWK8+tEukRRbtoOTxkV10sw5HexyTy9PRMxYbiJUhKOR0VgXB4HAH055qyZVnQbpMnafvn+LHJPr/APXPtUo0qSWTIiVY8/xc455x/Orem6EscgaZFYA52gYrr/td22MHlluplFEb5mN1k8/Icr+FFdwlsAo2xjHviisnm1Tsi/7Oh3Z83sgJO5earCzklu3miVwtvGHZkycZbAye3eugnslfJU49sVLo2I9D8TRjdvaO3H3QRgS5PfI7ev8AKvYrr3Tyab1NjwZqZSRUaRhgjA/Hpj04/WvV9MujJtYkhHBbt+v4V4Hp05t7pCUwpALHH0/+tXqPhjVQYwJi23OFPoc/Tvn9K8DE0uSbR6uHqc0T1PS7pcjfjOMLt4HrxjvWtHJGqjB28855JH+f5VyOn3aviWM7m68jAxzW9aTh4s8c9V965btM3cb6GuuXbIxnuB2/GnAFSGY/L0647cVVtceWQqkkHptqwNwzgcAkjHFWps55QSLCFiMIdhHB+bt+NPJcoW56Zycc9eP1NVoizHgZBHRe/wClTgkfI2SMDABOKtSvsZ2sKpD5+YlsDkjGO3+f608LtJILKBjIOMe9ROrFjt4C8AH+ftTy3IVuvHHHNS2NIYEAADEB84xtyTV6JfN25KnaAOneq+SrKnGevX/PtVmP2wQe5PNNu4IcRtzlgSOtRnqDjn1p4QcnPT1PSlZQM56fzrJ66lLsQFMnJBB9Kj2sGbcy7c8DHOPz571PnOBtOaYy8jj361LXcaZERxgcfSqxhyCPvADvnP8AnirWPXqOtGKhxNE7GZJaOoJUZGO3X8qilt2CneqnHXkcf54rXPSobiMSDG0E+pPSoaNI1GY80CkN8oGSQQf8KieyVjwBn1zj8q2BZIDyzEelSLaxDGQSQc5J60uU09tY586em4FT07Z4pf7NDru2E7e4HSukWNEPyqAfUDFJ5a4A5wO2etHIL6wznRYRAYAJbPXNBsos5wAvQc5remtkK/IBntmols/nGTgdTijlGqz7nNS2jM7CNM+56d6ifTlRGaVVJA44/Oumuoo4wdpIGOmfesq6AYnr0570WNY1GzAmj52BF54Hbv2q7YacrqokUBQMYI5q5aWoGXwRk/5/lW3p9vjEh+UA/KMYzTQqlSxBFYny1xCce5AorXTIXAY/nRVWOXnZ8id+vFY2oyNbX2E4juE2vjuc8f1rYIHJPOOfpxWV4hi3WTSodrR5bp1/z/Wvs6qvFnhwdmK+0lCqsBw2O3pXRaJdPu3B8dgWbcRXJWc3+jMq43k4Ixnjt/WtnSmBQ/MxYEZwcA/r9fzrysdFStUXU7MLK3unregXx8oea4LBsbe+3jJx/WuusbhEUuFUk9M8EDv/AIV5NpFwwcFnI8s7gc9fb/PrXe6Nc+bFGXBVuw968iSseqnc7WwuV5IOc8FcdP8AOB+VakEkeRkbc88nI/8A1/4CuYs5OnzjYDwB6n/9X+elbVpLlBg8HlTWdyJxtqXzEF+bcQoHUD/9XapS5VNxyxYjHy9KZasCBuk5JOQe9OlyWwrBdv8AET+Nac2ljn5dbjzJtI+cbyBxio0kcsQ+QAOuBwao6jcCNvmIAZsDnr6YrQhtosxyCRiwHHvx+n/16z5tTTlsrsnRMsMjgd6nVRkADge3Tj/9dIigZwRkjjjNcTrnjS6ttXk06ytIoXjl2Ga8chSMdcDGB3BycjHHNbU4yqbGTaR3SkduM8U0sN2CeSfbivPV1TWRqdnP9vXU4i5drbSwGCA8Yc4yBhuN3oehG6thPE199gknPh+/WdZAiwBG+YHJznbnjHp3HrVulISaOrbbznhQDzUcgwCc5zxmuZtfEmoTW9zNJ4fvYlh2fISxZ8sAQoKgnAyePxx1qfQ9fvtRvPIuNEubKMJuMspOO3HKjnmodKSv5DuboUFc5/H1ppQn1/lTjIAcDj2pCS3p688Viy9RrLjGaTHFP2k9fTvTwBjsfwosguRomeoHHY0uzrnOPan4xSAkttUc0rCuxgGPr9Kbzipio60nAI68+9OwXImUjkg1GxAIznJ6DHepWOSajIJYkgY6daWxSKN8w80DHPTOe3+c1TjQtLhVYtitOaPzJWDZ27RwO/NPjhjQAlRkcdKi1zVTsirBa/vAXBVeuAP8/wCRV8YPCnpx1zRkkng4Hf1oQgk9euMEVSREm2OC+pGfein4J5GDRVEXPkBsZOOMmqd386ujMvPB47VbzyQP/wBVQTk8suTx6CvtDxGYFlGI0njdSskTY78qTx/h+Famk3BjuljbHltwfY9iahgVf7bSOUj/AEiNo8kD7wBKDP1x7etQAsrLkEEdsVxSpqcZUjojLlamegWEZZUkjOE+6RnrXVaFdnyzG3AQH5sEf57/AOTXE+GrszRlS2SPlOeOn+f1rrtJIQyZ+bgYH9f5/pXz9SLi2mezRfNsdxp0h2xsSfL9c5B5/wAmt5JV7nvjgda4+zkCsuQdhGcfh6VswXDEptwycD5W/HFc70NuXmR0EU+FYBz6EZ46VYF8QE+X5lBHoPascSOCRtBx09xT0myT0znjH60rmbpjdVjedl2knBz16etX9MmZCmSXYjBGeTVOT5wCex7d6VJSkqlTggZx/Kp5dblt3jynUI2Oc8CobhY7pPKniimj7o6bgfw6VkxzswQbsDPPbINWraZncKQASCfr/jWidjndPuVYPDWmQ6hDeWtubeZCcFGwOmOh46f171s9FxkbTzlRjJpiEkKfl2cYOetSZz+FaOo5bszsKOvzA89fU0x5Mdhx3pVOfU4PcUigknFQUhF7gA7j39KmjRQcsabggcZyKfgnJUn3P+FFgbJOATxxnmm9uD096McdcmlKqoOOO5oSIG84wM9ep7U4jBB5Hcijq3J+Y80hHIY9fY02DHZBHGT26YqIAKDknrnk5qQntj9MVEQSaQ0NJ5PYDgH1pgUCTPO4jrTz1Pr6UUmUhhDBgBjHf2pGHPXn6VIQCOaMZIosFyMD5TnPuBSqpDZNSbeD3HvTRzweOcD3p2DmFBUcFuaKd5T9mUD3op2JufHayEjOBkccc4FNkmGGG4Aj8DmnQGW4b91FIyt0YDp7fpWhZ6A8kqedznJx1yT/AFr6atjqdPRas82lhZ1Dn7d9mt6ZcIWPk3UUhxgHgjpnP9fxq54x019M8Z3mlR5crIAX2qvVQ3AU4A54H5iutuNGt7SyEhh2qGVgQeTj0Pb0q98SxbXnxVmnspY545YomLxsCOFAIyCfSvNnjZSblHQ644VRaizl9KsJ9OjW5mbMXUAAk89P88V22iyI4ZlJII6Z7ntUEkQMTqw5HB9xWRpcn2W4eJG+7I2ARyRXHUk53kzsppU2kei2w2kgluvOT9a0okOBhc8cDPOfwrJ0mUTxAgBMnBCSDg9a37HbgK+4M2Aq7uvpzXK2dFmWIx8u7a68cjnjp09qaXDQ4c7V6DJ56elTrAGzgDIPGCBildT5gJG0dgeh64/Lk1BSZTMnyZyxUevAJ+nYVKkyrGDGQpI3A9B70kyp82RjjjPTt0/KqczlQwyRj7o7/T8KGNK5t2xyhznp+FaNo79mzk8DkfiMfjWNYFmjXacrjGSK1I2KEMp+f8qLmc0bA9CSceooU56dPpUSun8RIyf4j+uO1PDAZBOOR0FUjmJe9BOPu8596TdxkU4YIAcdex5q0iWxI+cZ5x7c1OihWZlByTzkk+3HpSKfm6GpDngLjg859KaVxbiEhew3dcUhII+WkZV378AEnGT34/8ArUgQjJZic8nJ9sVTQDQG6uRinYwKVV6AnJ7UpG3GfWofcTI24IGMimnkjaKe/J70E4qdgIup984+lBB608rn60qp6npQO5GASemBTgh71J3o7dqLiuMC9zSAHdz936U9RgACnAelFwuNKsP43HtxRTskdzRT5hWPnfT9FSNU3IR0AwD+p9K17ewhgwzoN6cDOOf8+ta5twGwp6ckkdTXQpotoNMsXklC3F1Oi8ZzggHC++Axz7VtCLmzoq1VSRr/APCB6NdaekN5bvIzBWJMhGG64O3p+v61zF18GdMhvTdadeXKXHl7EWY71ZtvUtjpnPbp9BXqpVok+4zjAUnIGBnBODxgDn8PXrFeXP2GyubiRUSKGN5iHcIMKM5JzgD17dzXUkkrHnc873ufMesXsVjf3tq0ySTWsjRMFPUgkH+XT3rGhYi8juGDYdc5/lWPoUFzr+s3E0oC/abh7h88gAknHpXT3sKx3axxH7hxnGDxnJH5Vk0lc7VJto6jw7OQhVxuGcAdc/Uf57V2dhKAqfMcZ9ec/wCfWuG8Oq5jlYkhCQB6d8/0rt9NjYjDsQ3Q8gYP+f6VxSO5WsbcaDdkgPuGee1NnU7sMMgD5en51JGh24OQBgZxihlC7h1APB9RSMubUzrjo64BBBOD6j/P/wCqsdpW8zAYsCSc4ArW1RlRCXwSOnr+BrGiQNIS55J6560jVampZO5X5eF7ArgdR3rajIZePzrHtD0Xc29WwSy9cjqDjke+a2bVQ0iDqDxkDGaCJl+MuwJkVcuQVOe4/HNWoyq7QvTHB6/56UzG1wdzkfxDdkD/ADinhC2C45BOKtHI2SJwuDypPcdKnQA54I56GoQAMEnOQT7ipI16HnGO5rT1M2TjJH+IxSk4PajBHIx78Um7B+9VIAOcg/ypuOSefp604fNnPOaRs5zj9aUnYLjTnA6g9jRyQSc0ZA6jn6Uu7A5/CswG0Yp+w9SeB37U3HJAqWA2nBSRkUbevGQO4pwA4zz7dPxosA3BA64oALKGIPNSqgHXHufx/wD1UuPnywx6U7CGBSQcgjpgUipkZPFS5YZU8+lOQYDDjB6VSSGReWx6GipQVUYJHHqaKegXPKpFxxtA3nGR69v616LFBFFp0OHTECg85wnAGRn2zzXDaCoudShR8YTLepyOma6O+eOzj1AgAlo0Bzk9SwPTngc/QV0UIkYqV3Y6W2mUQomPvdN2ec9sV438YfHOotr114N0pfKjnjWO4uDjlHX5kUnPJzjtgZ9sev2o861QKhBG1gJB83T+L1618+a8lv8A8Lf1hxE5ityjMJHJwwiUHJOSeQeT1rV2RlTV3qV202z8OQNbQRBrhYwrMx6ccknrjOePT9c2CBmmUk72fHKjP4/rVrVGkuLmTed2GPJJPT6irGjIHn+Yliq/e2/r7dK56jtc9ClG9rnR6FGscSF1Jwo4bI7fnXU2qDsm3B79RWLasAowencDHWtOKRyqksS3fjgcda5XudV7o2N2Rt6e3SmXE4gQtuPXr7fjVVXwcfMcnrjp3/Ci7Bcbmz0AGRx+NIhRV9TJv91xOxJ3AdfQc1NaocEAE5HHXK/5zTxajzA7EkZ3EEduvetC0QLj+6DjH9PpSNL2RNEhOCTgv1/lVu0R1b5ASwHAAqNQGPA6d81dtziHAGSxxwP61SRzTkTrKS2CQ3970NWwevt1qKNfuhgDjpj68VMAAAMZB4xVpGDYqfNjaMfUdTU6nG0DtUWQuM7tvpilQkNhiSOTzj1qjO5OWzng5/lRgOMPtxnj2NMyvG05FKMD1BouMdxzx0peO4znpSE8DFCksQBx+tFwGnGcjOPSgY/D1oPJyScdaTv2FRcB+MgkH3x0oTvgEH8zSBTkYzjsf61JyATjjvTEIUGADhT6044JJwMjrSgZBAyCe9KoIPOB2FMBpXoASD06UEh8dsH8qkxx7mkXPfpQABfp78daUD/61FLTAQUUUUCPKNMvWtNVheONeu0jtg11ugBNRttanuFJLXBt8A9E4GB2/iznHNFFb0W7DxUVzHZCNQOnPr7+v1rwW6t438ReKdUcb3lZZNpABBEaYyQAD19PzPNFFaN7GUFqYDWYke8G8gQp5nu3zKMfrRpDlJ5EHdc/5/OiisKh30XqjqIJCFVmJbK5Pv2rSt180DnblsfTBoornlsdC3Lbt5UMb43Etgc9OKc+7yiHbfjg579R/T9aKKguxPaRo8YbaOc8HmrkcaqSQBuwecdaKKZjLcswKCec4B6Zq/Eytvbbjb8316+lFFX0OeW5ZjPygfUdfepgMJRRSTIYmSwK+opR98DrkHr9aKK02RlLcevTntxTwQqkBeT3ooqG7XGtgPVffikxwSOmQMUUUMbAcn04/pTjxGD6miihALuIVcEg4/rUqoNpH4f0oopoGObhSc570LyAT9aKKoQ4DJAocfNgE8Giin0EFFFFIAooooGf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the accessory hillock (composed of skin, subcutaneous fat, and/or cartilage) near the border of the sternocleidomastoid muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_33_37407=[""].join("\n");
var outline_f36_33_37407=null;
